KR102755795B1 - Method of manufacturing diet pills - Google Patents
Method of manufacturing diet pills Download PDFInfo
- Publication number
- KR102755795B1 KR102755795B1 KR1020240016945A KR20240016945A KR102755795B1 KR 102755795 B1 KR102755795 B1 KR 102755795B1 KR 1020240016945 A KR1020240016945 A KR 1020240016945A KR 20240016945 A KR20240016945 A KR 20240016945A KR 102755795 B1 KR102755795 B1 KR 102755795B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- herbal medicine
- powder
- prepare
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000006187 pill Substances 0.000 title claims abstract description 44
- 238000004519 manufacturing process Methods 0.000 title claims description 39
- 235000005911 diet Nutrition 0.000 title abstract description 52
- 230000037213 diet Effects 0.000 title abstract description 51
- 235000008434 ginseng Nutrition 0.000 claims abstract description 23
- 108010004032 Bromelains Proteins 0.000 claims abstract description 18
- 239000004365 Protease Substances 0.000 claims abstract description 18
- 235000019835 bromelain Nutrition 0.000 claims abstract description 18
- 241000218671 Ephedra Species 0.000 claims abstract description 15
- 244000248557 Ophiopogon japonicus Species 0.000 claims abstract description 14
- 241000405911 Rehmannia glutinosa Species 0.000 claims abstract description 14
- 241000132012 Atractylodes Species 0.000 claims abstract description 8
- 241000411851 herbal medicine Species 0.000 claims description 159
- 239000000843 powder Substances 0.000 claims description 63
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 42
- 239000011707 mineral Substances 0.000 claims description 42
- 238000002156 mixing Methods 0.000 claims description 41
- 238000009835 boiling Methods 0.000 claims description 31
- 240000004371 Panax ginseng Species 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000008213 purified water Substances 0.000 claims description 16
- 235000002789 Panax ginseng Nutrition 0.000 claims description 14
- 244000241838 Lycium barbarum Species 0.000 claims description 12
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 12
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 12
- 235000011613 Pinus brutia Nutrition 0.000 claims description 12
- 241000018646 Pinus brutia Species 0.000 claims description 12
- 235000018597 common camellia Nutrition 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 12
- 239000000419 plant extract Substances 0.000 claims description 12
- 240000001548 Camellia japonica Species 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 11
- 244000197580 Poria cocos Species 0.000 claims description 10
- 235000008599 Poria cocos Nutrition 0.000 claims description 10
- 239000010440 gypsum Substances 0.000 claims description 10
- 229910052602 gypsum Inorganic materials 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 9
- 235000015468 Lycium chinense Nutrition 0.000 claims description 9
- 241001522129 Pinellia Species 0.000 claims description 9
- 244000299790 Rheum rhabarbarum Species 0.000 claims description 9
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 9
- 238000005406 washing Methods 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 8
- 238000000227 grinding Methods 0.000 claims description 8
- 239000010453 quartz Substances 0.000 claims description 8
- WKBPZYKAUNRMKP-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)pentyl]1,2,4-triazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1C(CCC)CN1C=NC=N1 WKBPZYKAUNRMKP-UHFFFAOYSA-N 0.000 claims description 7
- 239000011031 topaz Substances 0.000 claims description 7
- 229910052853 topaz Inorganic materials 0.000 claims description 7
- 240000008917 Glycyrrhiza uralensis Species 0.000 claims description 6
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 claims description 6
- 239000004927 clay Substances 0.000 claims description 6
- 240000002045 Guettarda speciosa Species 0.000 claims description 5
- 208000008589 Obesity Diseases 0.000 claims description 5
- 239000010433 feldspar Substances 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 230000035800 maturation Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 abstract description 13
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract description 13
- 241000208340 Araliaceae Species 0.000 abstract description 2
- 241000208689 Eucommia ulmoides Species 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 42
- 230000000694 effects Effects 0.000 description 34
- 238000000034 method Methods 0.000 description 20
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 18
- 239000000306 component Substances 0.000 description 18
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 16
- 241000196324 Embryophyta Species 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 10
- 230000003078 antioxidant effect Effects 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 230000003110 anti-inflammatory effect Effects 0.000 description 8
- 235000012239 silicon dioxide Nutrition 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 7
- 229940124595 oriental medicine Drugs 0.000 description 7
- 241000202807 Glycyrrhiza Species 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 4
- 244000061520 Angelica archangelica Species 0.000 description 4
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 4
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 4
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000002292 Radical scavenging effect Effects 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000037228 dieting effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 244000237330 gutta percha tree Species 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 229940010454 licorice Drugs 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- 240000001810 Angelica gigas Species 0.000 description 3
- 235000018865 Angelica gigas Nutrition 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 244000184734 Pyrus japonica Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 235000001916 dieting Nutrition 0.000 description 3
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 208000006750 hematuria Diseases 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000010445 mica Substances 0.000 description 3
- 229910052618 mica group Inorganic materials 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- FMCGSUUBYTWNDP-ONGXEEELSA-N (1R,2S)-2-(dimethylamino)-1-phenyl-1-propanol Chemical compound CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 FMCGSUUBYTWNDP-ONGXEEELSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 244000001632 Acorus gramineus Species 0.000 description 2
- 235000013073 Acorus gramineus Nutrition 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 241000208838 Asteraceae Species 0.000 description 2
- 241000092665 Atractylodes macrocephala Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 235000007516 Chrysanthemum Nutrition 0.000 description 2
- 240000005250 Chrysanthemum indicum Species 0.000 description 2
- 241000243681 Eisenia bicyclis Species 0.000 description 2
- 241001465251 Ephedra sinica Species 0.000 description 2
- 241000218670 Ephedraceae Species 0.000 description 2
- AGBCLJAHARWNLA-DQUQINEDSA-N Ginsenoside RG2 Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@@](C)(O)CCC=C(C)C)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O AGBCLJAHARWNLA-DQUQINEDSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- IOLDDENZPBFBHV-UHFFFAOYSA-N Kukoamine A Chemical compound C1=C(O)C(O)=CC=C1CCC(=O)NCCCNCCCCNCCCNC(=O)CCC1=CC=C(O)C(O)=C1 IOLDDENZPBFBHV-UHFFFAOYSA-N 0.000 description 2
- 241001532026 Liriope muscari Species 0.000 description 2
- FMCGSUUBYTWNDP-UHFFFAOYSA-N N-Methylephedrine Natural products CN(C)C(C)C(O)C1=CC=CC=C1 FMCGSUUBYTWNDP-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 240000007263 Pinus koraiensis Species 0.000 description 2
- 235000011615 Pinus koraiensis Nutrition 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- RKFAZBXYICVSKP-AATRIKPKSA-N alpha-asarone Chemical compound COC1=CC(OC)=C(\C=C\C)C=C1OC RKFAZBXYICVSKP-AATRIKPKSA-N 0.000 description 2
- WUOACPNHFRMFPN-UHFFFAOYSA-N alpha-terpineol Chemical compound CC1=CCC(C(C)(C)O)CC1 WUOACPNHFRMFPN-UHFFFAOYSA-N 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 235000014590 basal diet Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- SQIFACVGCPWBQZ-UHFFFAOYSA-N delta-terpineol Natural products CC(C)(O)C1CCC(=C)CC1 SQIFACVGCPWBQZ-UHFFFAOYSA-N 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 235000005686 eating Nutrition 0.000 description 2
- 230000007937 eating Effects 0.000 description 2
- 229960002179 ephedrine Drugs 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 238000010230 functional analysis Methods 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 239000010977 jade Substances 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 229910000476 molybdenum oxide Inorganic materials 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 2
- 229940073569 n-methylephedrine Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 2
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 2
- 229960000395 phenylpropanolamine Drugs 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000000191 radiation effect Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 229940116411 terpineol Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- OSELKOCHBMDKEJ-UHFFFAOYSA-N (10R)-3c-Hydroxy-10r.13c-dimethyl-17c-((R)-1-methyl-4-isopropyl-hexen-(4c)-yl)-(8cH.9tH.14tH)-Delta5-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 OSELKOCHBMDKEJ-UHFFFAOYSA-N 0.000 description 1
- AGBCLJAHARWNLA-UHFFFAOYSA-N (20R)-ginsenoside Rg2 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C3C(C)(C)C(O)CCC3(C)C3C(C4(CCC(C4C(O)C3)C(C)(O)CCC=C(C)C)C)(C)C2)OC(CO)C(O)C1O AGBCLJAHARWNLA-UHFFFAOYSA-N 0.000 description 1
- CKUVNOCSBYYHIS-UHFFFAOYSA-N (20R)-ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O CKUVNOCSBYYHIS-UHFFFAOYSA-N 0.000 description 1
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 description 1
- RAQNTCRNSXYLAH-RFCGZQMISA-N (20S)-ginsenoside Rh1 Chemical compound O([C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RAQNTCRNSXYLAH-RFCGZQMISA-N 0.000 description 1
- CKUVNOCSBYYHIS-IRFFNABBSA-N (20S)-ginsenoside Rh2 Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-IRFFNABBSA-N 0.000 description 1
- OCZVHBZNPVABKX-UHFFFAOYSA-N 1,1-diphenyl-2-(2,4,6-trinitrophenyl)hydrazine;ethanol Chemical compound CCO.[O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NN(C=1C=CC=CC=1)C1=CC=CC=C1 OCZVHBZNPVABKX-UHFFFAOYSA-N 0.000 description 1
- CKUVNOCSBYYHIS-LGYUXIIVSA-N 20(R)-Ginsenoside Rh2 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3[C@](C)([C@@]4(C)[C@H]([C@H](O)C3)[C@@H]([C@](O)(CC/C=C(\C)/C)C)CC4)CC2)CC1 CKUVNOCSBYYHIS-LGYUXIIVSA-N 0.000 description 1
- CQSRUKJFZKVYCY-UHFFFAOYSA-N 5alpha-isofucostan-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 CQSRUKJFZKVYCY-UHFFFAOYSA-N 0.000 description 1
- 241000173529 Aconitum napellus Species 0.000 description 1
- 235000003840 Amygdalus nana Nutrition 0.000 description 1
- 244000296825 Amygdalus nana Species 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 241000045403 Astragalus propinquus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 229910021532 Calcite Inorganic materials 0.000 description 1
- 241000209507 Camellia Species 0.000 description 1
- 241000208365 Celastraceae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 244000077995 Coix lacryma jobi Species 0.000 description 1
- 235000007354 Coix lacryma jobi Nutrition 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 229920002138 Eckol Polymers 0.000 description 1
- ARZMNZGBFNSOIR-UHFFFAOYSA-N Eckol Natural products OC1=CC(O)=C2OC3=CC(C)=CC(O)=C3OC2=C1OC1=CC(O)=CC(O)=C1 ARZMNZGBFNSOIR-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- GBBBJSKVBYJMBG-QTWVXCTBSA-N Fucosterol Natural products CC=C(CC[C@@H](C)[C@@H]1CC[C@@H]2[C@H]3C=C[C@@H]4C[C@H](O)CC[C@@]4(C)[C@@H]3CC[C@@]12C)C(C)C GBBBJSKVBYJMBG-QTWVXCTBSA-N 0.000 description 1
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 description 1
- RAQNTCRNSXYLAH-UHFFFAOYSA-N Ginsenoside Rh1 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(C3)C)(C)C1C(O)CC2C1(C)CCC(O)C(C)(C)C1C3OC1OC(CO)C(O)C(O)C1O RAQNTCRNSXYLAH-UHFFFAOYSA-N 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- OSELKOCHBMDKEJ-VRUYXKNBSA-N Isofucosterol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C OSELKOCHBMDKEJ-VRUYXKNBSA-N 0.000 description 1
- 241001466453 Laminaria Species 0.000 description 1
- 241001466452 Laminariaceae Species 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 235000019738 Limestone Nutrition 0.000 description 1
- 241001106041 Lycium Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 240000009164 Petroselinum crispum Species 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 241000218641 Pinaceae Species 0.000 description 1
- 241001522232 Pinellia ternata Species 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 235000011432 Prunus Nutrition 0.000 description 1
- 240000005049 Prunus salicina Species 0.000 description 1
- 235000012904 Prunus salicina Nutrition 0.000 description 1
- 235000003681 Prunus ussuriensis Nutrition 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 241000612118 Samolus valerandi Species 0.000 description 1
- 102000011842 Serrate-Jagged Proteins Human genes 0.000 description 1
- 108010036039 Serrate-Jagged Proteins Proteins 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 235000000336 Solanum dulcamara Nutrition 0.000 description 1
- 241000736285 Sphagnum Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 1
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229940023019 aconite Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 1
- 239000010428 baryte Substances 0.000 description 1
- 229910052601 baryte Inorganic materials 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- RKFAZBXYICVSKP-UHFFFAOYSA-N beta- asarone Natural products COC1=CC(OC)=C(C=CC)C=C1OC RKFAZBXYICVSKP-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- RKFAZBXYICVSKP-WAYWQWQTSA-N beta-asarone Chemical compound COC1=CC(OC)=C(\C=C/C)C=C1OC RKFAZBXYICVSKP-WAYWQWQTSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
- 235000020827 calorie restriction Nutrition 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 238000012272 crop production Methods 0.000 description 1
- 235000021051 daily weight gain Nutrition 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000020870 detox diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- FZFYOUJTOSBFPQ-UHFFFAOYSA-M dipotassium;hydroxide Chemical compound [OH-].[K+].[K+] FZFYOUJTOSBFPQ-UHFFFAOYSA-M 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- PCZZRBGISTUIOA-UHFFFAOYSA-N eckol Chemical compound OC1=CC(O)=CC(OC=2C=3OC4=C(O)C=C(O)C=C4OC=3C(O)=CC=2O)=C1 PCZZRBGISTUIOA-UHFFFAOYSA-N 0.000 description 1
- -1 eckol and diekol Natural products 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- OSELKOCHBMDKEJ-JUGJNGJRSA-N fucosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC\C(=C/C)C(C)C)[C@@]1(C)CC2 OSELKOCHBMDKEJ-JUGJNGJRSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 235000004280 healthy diet Nutrition 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 239000006028 limestone Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- JURZHOVRCOWZFN-UHFFFAOYSA-N notoginsenoside R1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(CC34C)OC6OC(COC7OCC(O)C(O)C7O)C(O)C(O)C6O)C JURZHOVRCOWZFN-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000010450 olivine Substances 0.000 description 1
- 229910052609 olivine Inorganic materials 0.000 description 1
- 235000013348 organic food Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- PQQKPALAQIIWST-UHFFFAOYSA-N oxomolybdenum Chemical compound [Mo]=O PQQKPALAQIIWST-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 229930015698 phenylpropene Natural products 0.000 description 1
- QROGIFZRVHSFLM-UHFFFAOYSA-N phenylpropene group Chemical class C1(=CC=CC=C1)C=CC QROGIFZRVHSFLM-UHFFFAOYSA-N 0.000 description 1
- 229920001339 phlorotannin Polymers 0.000 description 1
- 229930182676 phlorotannins Natural products 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 235000014774 prunus Nutrition 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003044 randomized block design Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 235000020989 red meat Nutrition 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/38—Multiple-step
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 마황, 백출, 의이인, 숙지황, 인삼, 맥문동 및 브로멜라인을 포함하는 다이어트 환을 제공한다.The present invention provides a diet pill containing ephedra, white atractylodes, eucommia ulmoides, rehmannia glutinosa, ginseng, Ophiopogon japonicus and bromelain.
Description
본 발명은 다이어트 환 및 이의 제조방법에 관한 것이다.The present invention relates to a diet pill and a method for manufacturing the same.
급속한 산업 발전과 경제수준의 향상과 함께 식생활의 변화와 신체 활동량이 감소되면서 비만 인구가 증가하고 있다. 세계보건기구에는 비만을 단순한 증상이 아닌 질병으로 규정하고 있는 정도로 비만은 심각한 사회적 문제로 대두되고 있고 심리적, 사회적으로 개인을 위축시키고, 특히 우리 사회에서 비만이나 과체중은 바람직하지 않게 여겨지고 있는 까닭에 다이어트에 대한 관심은 식지 않고 있다. 다이어트 관련한 식품의 인기는 계속될 것으로 전망되며, 비만의 예방과 미용에 대한 소비자 니즈가 점차 높아짐에 따라 다이어트 관련 제품의 개발이 필요하게 되었다.With rapid industrial development and economic growth, changes in eating habits and a decrease in physical activity are leading to an increase in the obese population. The World Health Organization defines obesity as a disease, not a simple symptom, and obesity is emerging as a serious social problem. It psychologically and socially discourages individuals, and because obesity and overweight are considered undesirable in our society in particular, interest in dieting is not fading. The popularity of diet-related foods is expected to continue, and as consumer needs for obesity prevention and beauty gradually increase, the development of diet-related products has become necessary.
한편, 미세먼지, 황사를 비롯한 각종 유해물질뿐 아니라, 대사과정에서 생성되는 노폐물이나 활성산소, 염증유발물질 등의 신체적 독소, 분노나 스트레스 등과 같은 마음의 독소 등이 현대인들을 위협하고 있다. 이들은 모두 현대의학에서도 대부분의 만성질환, 암 등의 주 원인으로 지목되는 것이다. 특히, 오늘날 대량으로 생산되는 농, 축산 시스템에서는 가축의 사료인 곡물의 대량 생산을 위해 다량의 제초제와 살충제가 사용되며, 사육과정에서 항생제와 성장촉진제 등이 투여되고, 가공과정에서는 각종 화학첨가물들이 섞여 들어가고 있다. 이런 오염된 화학물질들은 대개 지방친화적이어서 가축들의 지방조직에 축적된다. 그리고 이들을 먹은 우리 몸속의 지방 조직에 다시 축적된다. 인간이 화학첨가물들의 최종 정착지인 샘이다. 이들은 우리 몸속에서 만성적인 염증을 유발시키며 세포의 엔진에 해당되는 미토콘드리아를 손상시키고, 면역기능을 떨어뜨리며, 호르몬 체계를 교란시켜 각종 암이 유발되는데 기여한다. 암 발생률이 육류, 특히 붉은 고기와 가공육, 유제품 소비량과 직접적인 관계가 있다는 것은 잘 알려진 사실이다. 육류와 유제품 그 자체가 나쁘다기보다는 건강하지 않게 사육된 축산물을 섭취함으로써 체내에서 염증을 유발할 수 있는 각종 화학물질들을 농축된 형태로 섭취하는 것이 문제라는 것이다.Meanwhile, not only various harmful substances such as fine dust and yellow dust, but also waste products, active oxygen, and inflammatory substances generated during the metabolic process, physical toxins such as anger and stress, and mental toxins such as anger and stress are threatening modern people. All of these are pointed out as the main causes of most chronic diseases, cancer, etc. in modern medicine. In particular, in today's mass-produced agricultural and livestock systems, large amounts of herbicides and pesticides are used to mass-produce grains as livestock feed, antibiotics and growth promoters are administered during the breeding process, and various chemical additives are mixed in during the processing process. These polluted chemicals are usually lipophilic and accumulate in the fat tissue of livestock. And they are accumulated again in the fat tissue of our bodies that eat them. Humans are the final destination of chemical additives. They cause chronic inflammation in our bodies, damage mitochondria, which are the engines of cells, reduce immune function, and disrupt the hormonal system, contributing to the development of various cancers. It is a well-known fact that cancer incidence is directly related to the consumption of meat, especially red meat, processed meat, and dairy products. The problem is not that meat and dairy products are bad in themselves, but rather that by consuming unhealthy animal products, we are consuming concentrated forms of various chemicals that can cause inflammation in the body.
이처럼 건강을 위협하는 요소들이 늘어나다 보니, 건강에 대한 관심이 급증하고 있고, 최근에 몸 안의 독소를 빼는 이른바 '디톡스'라는 말이 유행하면서, 디톡스 다이어트, 디톡스 주스 등에 대한 관심이 급증하였다. 디톡스(detox)는 detoxification의 약어로 몸 안의 독소를 없애는 것을 의미한다. 유해물질이 몸 안으로 과다하게 들어오는 것을 막고, 장이나 신장, 폐, 피부 등을 통한 노폐물의 배출을 촉진하는 것이다. 칼로리 제한에 의해 다이어트 효과가 있어 건강 다이어트 방법으로 많이 사용되며, 서양에서는 니라 드링크만 마시는 레몬 디톡스법이 알려져 있고, 한국에서는 장 청소와 단식이 대표적으로 시행되고 있다. 물만 마시거나 한가지 음식만 먹는 방법도 있으며, 유기농산물, 제철음식을 주로 하며 비타민과 미네랄을 충분히 섭취해야 하고 가공식품, 육류, 소금, 설탕을 멀리 하는 것이 원칙이다. 음식뿐만 아니라 유해물질로 가득찬 주거환경을 천연마감재로 바꾸고, 마음속의 스트레스를 불러일으키는 분노, 짜증 등을 다스리는 명상 등도 넓은 의미의 디톡스라 할 수 있다. 디톡스는 주로 균형 잡힌 식이요법을 통한 해독 방법으로 알려져 있다. 즉, 유기농으로 재배된 제철 과일과 채소 등을 충분히 섭취하는 것이다.As the number of factors threatening health increases, interest in health is rapidly increasing, and recently, as the term 'detox', which removes toxins from the body, has become popular, interest in detox diets and detox juices has also rapidly increased. Detox is an abbreviation for detoxification, which means removing toxins from the body. It prevents excessive harmful substances from entering the body and promotes the excretion of waste through the intestines, kidneys, lungs, and skin. It is widely used as a healthy diet method because it has a diet effect due to calorie restriction. In the West, the lemon detox method of drinking only nia drink is well known, and in Korea, intestinal cleansing and fasting are representative methods. There are also methods of drinking only water or eating only one type of food, and the principle is to mainly eat organic produce and seasonal foods, consume sufficient vitamins and minerals, and stay away from processed foods, meat, salt, and sugar. In addition to food, changing the living environment full of harmful substances to natural finishing materials and meditation to control anger and irritation that cause mental stress can also be considered detox in a broad sense. Detox is known primarily as a method of detoxification through a balanced diet, that is, eating plenty of seasonal fruits and vegetables grown organically.
한편, 마황(Ephedra sinica)은 마황과(Ephedraceae) 식물로, 가을에 목질화되지 않은 줄기를 베어 말려서 사용한다. 마황은 한방에서 감기, 천식 등의 치료에 사용되어 왔으며, 약리적 성분으로서 에페드린, N-메틸에페드린, 노르에페드린, 벤질메틸아민 및 터피네올 등을 함유하는 것으로 알려져 있다. 마황은 다량 섭취하는 경우 혈압 상승이나 입마름과 같은 부작용을 유발할 수 있으나, 적절히 사용하면 섭취하거나 피부 및 점막 등에 적용하여도 안전하여 다양한 질환을 치료하기 위한 한방 제제에 치료 성분으로서 사용되고 있다.Meanwhile, Ephedra sinica is a plant of the Ephedraceae family. In the fall, the stems that have not become lignified are cut and dried for use. Ephedra has been used in oriental medicine to treat colds, asthma, etc., and is known to contain ephedrine, N-methylephedrine, norephedrine, benzylmethylamine, and terpineol as pharmacological ingredients. Ephedra can cause side effects such as increased blood pressure or dry mouth when consumed in large quantities, but it is safe to ingest or apply to the skin and mucous membranes when used appropriately, and is used as a therapeutic ingredient in oriental medicine preparations to treat various diseases.
또한, 백출(Atractylodes macrocephala)은 국화과(菊花科 Asteraceae)에 속하는 다년생초본인 삽주의 뿌리덩어리(塊莖)로 외면은 회색 또는 담갈색을 띠고 있다. 절단면은 황백색인데 지방이 풍부하고 약간 섬유성이며 특이한 방향성 냄새가 난다. 채취는 10~11월에 하며 가는 뿌리와 줄기 및 잎을 제거하고 건조시킨다. 성분은 휘발성 정유와 비타민 A,비타민 D를 함유하고 있다. 성질은 따뜻하고 약간 향이 있고 독이 없으며, 맛은 약간 쓴맛이 도는 단맛이다. 효능은 몸을 무겁게 하는 여분의 습기를 말리며 소변이 잘 배출되도록 한다. 또한 피부가 약해져서 헛땀이 나는 것을 방지하고 태반 및 태아를 안정시키는 작용 등을 한다. Also, Atractylodes macrocephala is the root mass of the perennial herb Asteraceae, which has a gray or light brown exterior. The cut surface is yellowish white, rich in fat, slightly fibrous, and has a unique aromatic smell. It is harvested in October to November, and the thin roots, stems, and leaves are removed and dried. Its ingredients include volatile essential oils, vitamin A, and vitamin D. Its properties are warm, slightly fragrant, non-toxic, and its taste is slightly bitter and sweet. Its efficacy is to dry excess moisture that weighs down the body and to facilitate urination. It also prevents skin from becoming weak and causing dry sweating, and has the effect of stabilizing the placenta and fetus.
본 발명은 상기와 같은 문제점을 해결하기 위해 안출된 것으로서, 본 발명의 목적은 다이어트 효과가 우수한 다이어트 환을 제공하는 것이다.The present invention has been made to solve the above problems, and the purpose of the present invention is to provide a diet pill with excellent dieting effects.
본 발명의 다른 목적은 우수한 다이어트 효과와 함께 디톡스 효과를 가지는 다이어트 환을 제공하는 것이다.Another object of the present invention is to provide a diet pill having a detox effect along with an excellent diet effect.
본 발명의 또 다른 목적은 항산화, 항염, 다이어트 효과 및 디톡스 효과를 가지는 환을 제공하는 것이다.Another object of the present invention is to provide a pill having antioxidant, anti-inflammatory, dieting and detoxifying effects.
본 발명의 과제는 이상에서 언급한 과제들로 제한되지 않으며, 언급되지 않은 또 다른 과제들은 아래의 기재로부터 당업자에게 명확하게 이해될 수 있을 것이다.The tasks of the present invention are not limited to the tasks mentioned above, and other tasks not mentioned will be clearly understood by those skilled in the art from the description below.
상기 목적을 달성하기 위하여 본 발명은In order to achieve the above purpose, the present invention
마황, 백출, 의이인, 숙지황, 인삼, 맥문동 및 브로멜라인을 포함하는 다이어트 환을 제공한다.We provide diet pills containing ephedra, white atractylodes, eucommia ulmoides, rehmannia glutinosa, ginseng, Ophiopogon japonicus, and bromelain.
또한, 상기 다이어트 환은,In addition, the above diet pills,
마황 44-48 중량부, 백출 9-13 중량부, 의이인 13-17 중량부, 숙지황 9-13 중량부, 인삼 9-13 중량부 및 맥문동 4-8 중량부를 혼합하여 제1 약재를 제조하고, 상기 제1 약재를 약포대에 넣어 제1 약포대를 제조하는 단계;A step of preparing a first herbal medicine by mixing 44-48 parts by weight of Ephedra, 9-13 parts by weight of White Chrysanthemum, 13-17 parts by weight of Euicorea japonica, 9-13 parts by weight of Rehmannia glutinosa, 9-13 parts by weight of Panax ginseng, and 4-8 parts by weight of Ophiopogon japonicus, and placing the first herbal medicine in a herbal medicine pouch to prepare a first herbal medicine pouch;
석고 10-14 중량부, 대황 9-13 중량부, 구기자 9-13 중량부, 반하 9-13 중량부, 당귀 9-13 중량부, 감초 9-13 중량부, 석창포 9-13 중량부, 복령 9-13 중량부 및 황기 9-13 중량부를 혼합하여 제2 약재를 제조하고, 상기 제2 약재를 약포대에 넣어 제2 약포대를 제조하는 단계;A step of preparing a second herbal medicine by mixing 10-14 parts by weight of gypsum, 9-13 parts by weight of rhubarb, 9-13 parts by weight of wolfberry, 9-13 parts by weight of pinellia, 9-13 parts by weight of angelica, 9-13 parts by weight of licorice, 9-13 parts by weight of Seokchangpo, 9-13 parts by weight of Poria cocos, and 9-13 parts by weight of Astragali, and placing the second herbal medicine in a herbal medicine pouch to prepare a second herbal medicine pouch;
상기 제1 약포대 및 상기 제2 약포대를 정제수를 포함하는 전탕기에 넣고, 138-142℃의 온도에서 160-200분 동안 전탕하는 단계;A step of placing the first and second herbal medicine bottles in a boiler containing purified water and boiling them at a temperature of 138-142°C for 160-200 minutes;
전탕 후, 제1 약포대 및 제2 약포대를 꺼내어 전탕액을 준비하고, 상기 전탕액을 농축하여 농축 전탕액을 제조하는 단계;After boiling, the first and second herbal medicine containers are taken out to prepare a boiling solution, and the boiling solution is concentrated to prepare a concentrated boiling solution;
꺼낸 제1 약포대의 제1 약재를 건조한 후 분쇄하여 제1 약재분말을 제조하는 단계; 및A step of drying and crushing the first medicinal herb from the first herbal medicine bag to produce the first medicinal herb powder; and
상기 제1 약재분말 78-82 중량부, 상기 농축 전탕액 8-12 중량부 및 브로멜라인 분말 8-12 중량부를 혼합하여 환을 제조하는 단계;를 수행하여 제조되는 것을 특징으로 한다.It is characterized in that it is manufactured by performing a step of manufacturing a pill by mixing 78-82 parts by weight of the first herbal medicine powder, 8-12 parts by weight of the concentrated decoction, and 8-12 parts by weight of bromelain powder.
또한, 본 발명은In addition, the present invention
마황 44-48 중량부, 백출 9-13 중량부, 의이인 13-17 중량부, 숙지황 9-13 중량부, 인삼 9-13 중량부 및 맥문동 4-8 중량부를 혼합하여 제1 약재를 제조하고, 상기 제1 약재를 약포대에 넣어 제1 약포대를 제조하는 단계; 석고 10-14 중량부, 대황 9-13 중량부, 구기자 9-13 중량부, 반하 9-13 중량부, 당귀 9-13 중량부, 감초 9-13 중량부, 석창포 9-13 중량부, 복령 9-13 중량부 및 황기 9-13 중량부를 혼합하여 제2 약재를 제조하고, 상기 제2 약재를 약포대에 넣어 제2 약포대를 제조하는 단계; 상기 제1 약포대 및 상기 제2 약포대를 정제수를 포함하는 전탕기에 넣고, 138-142℃의 온도에서 160-200분 동안 전탕하는 단계; 전탕 후, 제1 약포대 및 제2 약포대를 꺼내어 전탕액을 준비하고, 상기 전탕액을 농축하여 농축 전탕액을 제조하는 단계; 및 꺼낸 제1 약포대의 제1 약재를 건조한 후 분쇄하여 제1 약재분말을 제조하는 단계;를 포함하는 농축 전탕액 및 제1 약재분말을 제조하는 단계;A step of preparing a first herbal medicine by mixing 44-48 parts by weight of Ephedra, 9-13 parts by weight of White Atractylodes, 13-17 parts by weight of Eui-in, 9-13 parts by weight of Rehmannia glutinosa, 9-13 parts by weight of Panax ginseng, and 4-8 parts by weight of Ophiopogon japonicus, and placing the first herbal medicine in a herbal medicine pouch to prepare a first herbal medicine pouch; A step of preparing a second herbal medicine by mixing 10-14 parts by weight of Gypsum, 9-13 parts by weight of Rhubarb, 9-13 parts by weight of Wolfberry, 9-13 parts by weight of Pinellia sinensis, 9-13 parts by weight of Angelica, 9-13 parts by weight of Glycyrrhiza uralensis, 9-13 parts by weight of Seokchangpo, 9-13 parts by weight of Poria cocos, and 9-13 parts by weight of Astragali, and placing the second herbal medicine in a herbal medicine pouch to prepare a second herbal medicine pouch; A step for preparing a concentrated decoction solution and a first herbal medicine powder, comprising the steps of: placing the first herbal medicine bag and the second herbal medicine bag in a boiler containing purified water, and boiling at a temperature of 138-142°C for 160-200 minutes; after boiling, taking out the first herbal medicine bag and the second herbal medicine bag to prepare a decoction solution, and concentrating the decoction solution to prepare a concentrated decoction solution; and drying and pulverizing the first herbal medicine in the taken out first herbal medicine bag to prepare a first herbal medicine powder;
견운모, 석영, 황옥, 맥반석 및 황토를 세척한 후, 분쇄하고 1:1:1:1:1의 중량비율로 혼합하여 광물분말을 제조하는 단계; 상기 광물분말 28-32 중량부 및 정제수 68-72 중량부를 혼합하여 광물혼합물을 제조하는 단계; 상기 광물혼합물을 118-122℃의 온도로 가열하여 5-7시간 동안 추출하는 단계; 가열 후 28-32℃의 온도에서 2-4일 동안 숙성하는 단계; 및 숙성 후 여과하여 여과액을 얻는 단계;를 포함하는 광물용액을 제조하는 단계;A step for preparing a mineral solution, comprising: a step of preparing a mineral powder by washing mite, quartz, topaz, feldspar, and yellow clay, grinding them, and mixing them in a weight ratio of 1:1:1:1:1; a step of preparing a mineral mixture by mixing 28-32 parts by weight of the mineral powder and 68-72 parts by weight of purified water; a step of heating the mineral mixture at a temperature of 118-122°C and extracting it for 5-7 hours; a step of maturing it at a temperature of 28-32°C for 2-4 days after the heating; and a step of filtering it after the maturation to obtain a filtrate;
자두나무잎, 동백나무잎 및 잣나무잎을 세척한 후, 58-62℃의 온도에서 2-4시간 동안 건조하는 단계; 건조한 자두나무잎, 동백나무잎 및 잣나무잎을 분쇄하고, 1:1:1의 중량비율로 혼합하여 잎분말을 제조하는 단계; 상기 잎분말 8-12 중량부 및 상기 광물용액 88-92 중량부를 혼합하고, 88-92℃의 온도에서 8-10시간 동안 추출하여 추출액을 제조하는 단계; 및 상기 추출액을 여과지로 여과하고, 여과된 여과액을 영하 48-52℃에서 감압농축 및 동결건조하는 단계;를 포함하는 천연식물 추출물을 제조하는 단계; 및A step for preparing a natural plant extract, comprising: a step of washing plum leaves, camellia leaves and pine leaves, and drying them at a temperature of 58-62°C for 2-4 hours; a step of grinding the dried plum leaves, camellia leaves and pine leaves, and mixing them at a weight ratio of 1:1:1 to prepare a leaf powder; a step of mixing 8-12 parts by weight of the leaf powder and 88-92 parts by weight of the mineral solution, and extracting them at a temperature of 88-92°C for 8-10 hours; and a step of filtering the extract through a filter paper, and subjecting the filtered filtrate to reduced pressure concentration and freeze-drying at -48-52°C; and
상기 제1 약재분말 58-62 중량부, 상기 천연식물 추출물 18-22 중량부, 상기 농축 전탕액 8-12 중량부 및 브로멜라인 분말 8-12 중량부를 혼합하여 환을 제조하는 단계;를 포함하는 다이어트 환의 제조방법을 제공한다.The present invention provides a method for manufacturing a diet pill, comprising the step of manufacturing a pill by mixing 58-62 parts by weight of the first herbal medicine powder, 18-22 parts by weight of the natural plant extract, 8-12 parts by weight of the concentrated decoction, and 8-12 parts by weight of bromelain powder.
본 발명에 따른 다이어트 환은 우수한 다이어트 효과를 가진다.The diet pill according to the present invention has an excellent diet effect.
또한, 본 발명에 따른 다이어트 환은 항산화, 항염, 다이어트 효과 및 디톡스 효과를 가진다.In addition, the diet pill according to the present invention has antioxidant, anti-inflammatory, dieting and detoxifying effects.
이하에서는 다양한 실시예를 보다 상세하게 설명한다. 본 명세서에 기재된 실시예는 다양하게 변형될 수 있다. 특정한 실시예가 상세한 설명에서 자세하게 설명될 수 있다. 그러나 개시된 특정한 실시 예는 다양한 실시예를 쉽게 이해하도록 하기 위한 것일 뿐이다. 따라서 개시된 특정 실시예에 의해 기술적 사상이 제한되는 것은 아니며, 발명의 사상 및 기술 범위에 포함되는 모든 균등물 또는 대체물을 포함하는 것으로 이해되어야 한다.Hereinafter, various embodiments will be described in more detail. The embodiments described herein may be modified in various ways. Specific embodiments may be described in detail in the detailed description. However, the specific embodiments disclosed are only intended to facilitate easy understanding of various embodiments. Therefore, the technical idea is not limited by the specific embodiments disclosed, but should be understood to include all equivalents or substitutes included in the spirit and technical scope of the invention.
1차, 2차, 제1, 제2 등과 같이 서수를 포함하는 용어는 다양한 구성요소들을 설명하는데 사용될 수 있지만, 이러한 구성요소들은 상술한 용어에 의해 한정되지는 않는다. 상술한 용어는 하나의 구성요소를 다른 구성요소로부터 구별하는 목적으로만 사용된다.Terms that include ordinal numbers, such as primary, secondary, first, second, etc., may be used to describe various components, but these components are not limited by the above terms. The above terms are used only to distinguish one component from another.
본 명세서에서, '포함한다' 또는 '가지다' 등의 용어는 명세서상에 기재된 특징, 숫자, 단계, 동작, 구성요소, 부품 또는 이들을 조합한 것이 존재함을 지정하려는 것이지, 하나 또는 그 이상의 다른 특징들이나 숫자, 단계, 동작, 구성요소, 부품 또는 이들을 조합한 것들의 존재 또는 부가 가능성을 미리 배제하지 않는 것으로 이해되어야 한다. 어떤 구성요소가 다른 구성요소에 '연결되어' 있다거나 '접속되어' 있다고 언급된 때에는, 그 다른 구성요소에 직접적으로 연결되어 있거나 또는 접속되어 있을 수도 있지만, 중간에 다른 구성요소가 존재할 수도 있다고 이해되어야 할 것이다. 반면에, 어떤 구성요소가 다른 구성요소에 '직접 연결되어' 있다거나 '직접 접속되어' 있다고 언급된 때에는, 중간에 다른 구성요소가 존재하지 않는 것으로 이해되어야 할 것이다.In this specification, it should be understood that terms such as "include" or "have" are intended to specify the presence of a feature, number, step, operation, component, part or combination thereof described in the specification, but do not exclude in advance the possibility of the presence or addition of one or more other features, numbers, steps, operations, components, parts or combinations thereof. When it is stated that a certain component is "connected" or "connected" to another component, it should be understood that it may be directly connected or connected to the other component, but that other components may also exist in between. On the other hand, when it is stated that a certain component is "directly connected" or "directly connected" to another component, it should be understood that no other components exist in between.
그 밖에도, 본 발명을 설명함에 있어서, 관련된 공지 기능 혹은 구성에 대한 구체적인 설명이 본 발명의 요지를 불필요하게 흐릴 수 있다고 판단되는 경우, 그에 대한 상세한 설명은 축약하거나 생략한다.In addition, when describing the present invention, if it is determined that a specific description of a related known function or configuration may unnecessarily obscure the gist of the present invention, the detailed description thereof is abbreviated or omitted.
본 발명은The present invention
마황, 백출, 의이인, 숙지황, 인삼, 맥문동 및 브로멜라인을 포함하는 다이어트 환을 제공한다.We provide diet pills containing ephedra, white atractylodes, eucommia ulmoides, rehmannia glutinosa, ginseng, Ophiopogon japonicus, and bromelain.
이하, 본 발명에 따른 다이어트 환에 대하여 상세히 설명한다.Hereinafter, the diet pill according to the present invention will be described in detail.
마황(Ephedra sinica)은 마황과(Ephedraceae) 식물로, 가을에 목질화되지 않은 줄기를 베어 말려서 사용한다. 마황은 한방에서 감기, 천식 등의 치료에 사용되어 왔으며, 약리적 성분으로서 에페드린, N-메틸에페드린, 노르에페드린, 벤질메틸아민 및 터피네올 등을 함유하는 것으로 알려져 있다. 마황은 다량 섭취하는 경우 혈압 상승이나 입마름과 같은 부작용을 유발할 수 있으나, 적절히 사용하면 섭취하거나 피부 및 점막 등에 적용하여도 안전하여 다양한 질환을 치료하기 위한 한방 제제에 치료 성분으로서 사용되고 있다.Ephedra sinica is a plant in the Ephedraceae family. In the fall, the unwooded stems are cut, dried, and used. Ephedra has been used in oriental medicine to treat colds, asthma, etc., and is known to contain pharmacological ingredients such as ephedrine, N-methylephedrine, norephedrine, benzylmethylamine, and terpineol. Ephedra can cause side effects such as increased blood pressure or dry mouth when consumed in large quantities, but it is safe to ingest or apply to the skin and mucous membranes when used appropriately, and is used as a therapeutic ingredient in oriental medicine preparations to treat various diseases.
백출(Atractylodes macrocephala)은 국화과(菊花科 Asteraceae)에 속하는 다년생초본인 삽주의 뿌리덩어리(塊莖)로 외면은 회색 또는 담갈색을 띠고 있다. 절단면은 황백색인데 지방이 풍부하고 약간 섬유성이며 특이한 방향성 냄새가 난다. 채취는 10~11월에 하며 가는 뿌리와 줄기 및 잎을 제거하고 건조시킨다. 성분은 휘발성 정유와 비타민 A,비타민 D를 함유하고 있다. 성질은 따뜻하고 약간 향이 있고 독이 없으며, 맛은 약간 쓴맛이 도는 단맛이다. 효능은 몸을 무겁게 하는 여분의 습기를 말리며 소변이 잘 배출되도록 한다. 또한 피부가 약해져서 헛땀이 나는 것을 방지하고 태반 및 태아를 안정시키는 작용 등을 한다. Atractylodes macrocephala is the root mass of the perennial herb Asteraceae, which has a gray or light brown exterior. The cut surface is yellowish white, rich in fat, slightly fibrous, and has a unique aromatic odor. It is harvested in October to November, and the thin roots, stems, and leaves are removed and dried. It contains volatile essential oils, vitamin A, and vitamin D. It is warm, slightly fragrant, non-toxic, and has a slightly bitter sweet taste. Its efficacy is to dry excess moisture that weighs down the body and to promote urination. It also prevents skin from becoming weak and causing dry sweating, and stabilizes the placenta and fetus.
의이인은 율무(Coix lacryma-jobi Linne var. ma-yuen Stapf)(벼과 Gramineae)의 잘 익은 씨로서 씨껍질을 제거한 것이다. 차 등으로 먹거나 이뇨, 진통, 강장작용이 있으므로 부종, 신경통, 류머티즘, 방광결석 등에 약재로 사용한다.Coix lacryma-jobi Linne var. ma-yuen Stapf (Gramineae family) is the ripened seed with the seed husk removed. It is eaten as tea, etc., and is used as a medicine for edema, neuralgia, rheumatism, bladder stones, etc. because it has diuretic, analgesic, and tonic effects.
숙지황(Rehmanniae Radix preparata)은 혈류를 좋게 하여 허혈을 해소함으로써 신체의 냉증을 해소하고 혈류가 상대적으로 어려운 하초의 기운을 보충하며 각종 면역세포와 혈액세포의 증식 및 골수세포를 활성화 및 세포성 면역을 증진 효능이 있다고 알려져있어 보혈제로 많이 쓰인다.Rehmanniae Radix preparata is known to improve blood flow, relieve ischemia, relieve cold symptoms in the body, replenish the energy of the lower body where blood flow is relatively difficult, and promote the proliferation of various immune cells and blood cells, activate bone marrow cells, and enhance cellular immunity, so it is widely used as a blood tonic.
인삼(Panax ginseng)은 식물 분류학상으로 오갈피나무과(Araliaceae)의 인삼속(Panax)에 속하는 다년생 음지성 초본식물로서 오래 전부터 한방에서 중요한 약재로 사용되었다. 인삼은 일반적으로 가공 방법에 따라 백삼과 홍삼으로 구분되며, 백삼은 밭에서 채굴한 가공되지 아니한 인삼 즉, 수삼을 그대로 건조한 것을 지칭하며 홍삼은 수삼을 증숙하여 건조 가공한 것으로 제조 과정에서 사포닌 변형과 아미노산 변화 등 여러 화학적인 변화가 수반된다. 홍삼은 제조 과정에서 가해지는 열에 의해 인삼에 존재하지 않는 진세노사이드 Rg2, Rg3, Rh1, Rh2 등의 사포닌 성분이 생성되며, 홍삼 특유의 유효 성분은 암 예방 작용, 암세포 성장 억제 작용, 혈압 강하 작용, 뇌신경세포 보호 및 학습 능력 개선 작용, 항혈전 작용, 항산화 작용 등이 우수하다.Ginseng (Panax ginseng) is a perennial shade-loving herbaceous plant belonging to the genus Panax of the Araliaceae family in plant taxonomy, and has been used as an important medicinal ingredient in oriental medicine since long ago. Ginseng is generally classified into white ginseng and red ginseng depending on the processing method. White ginseng refers to unprocessed ginseng dug from the field, that is, fresh ginseng that is dried as is, and red ginseng is fresh ginseng that is steamed, dried, and processed. Various chemical changes such as saponin modification and amino acid changes occur during the manufacturing process. In the manufacturing process, saponin components such as ginsenoside Rg2, Rg3, Rh1, and Rh2 that do not exist in ginseng are generated due to the heat applied to red ginseng. The unique effective ingredients of red ginseng are excellent in preventing cancer, inhibiting cancer cell growth, lowering blood pressure, protecting brain neurons and improving learning ability, antithrombotic effect, and antioxidant effect.
맥문동(Liriope platyphylla)은 음지 습한 곳에서 잘 자라고, 7월에 보라색의 꽃이 피어 10월에는 검은색 열매를 맺는 백합과에 속하는 다년생 초본식물로서, 맥문동의 효능으로 혈당강하작용, 항염증작용, 항부정맥효과, 항암작용 등이 있는 것으로 보고된 바 있다.Liriope platyphylla is a perennial herbaceous plant belonging to the lily family that grows well in shady, moist places, blooms purple flowers in July, and bears black fruits in October. It has been reported that the efficacy of Liriope platyphylla includes hypoglycemic, anti-inflammatory, anti-arrhythmic, and anticancer effects.
브로멜라인(Bromelain)은 파인애플의 열매 및 줄기에 많이 들어있는 천연 단백질 분해효소로, 소화효소인 트립신(trypsin)과 펩신(pepsin)의 효과를 강화하여 소화를 돕고, 췌장액과 결합되어 소화불량에 사용된다. 브로멜라인은 소장에서 흡수되어 혈액을 따라 이동하면서 혈액 내 섬유소, 단백질, 불순물을 용해하여 혈액을 정화함과 동시에 혈액순환을 원활히 하여 심장병 예방 등에 효과적인 성분이다. 또한, 염증 완화 작용이 뛰어나 부작용 없이 관절염, 근육통, 인대 손상, 축농증 등 염증 관련 질환을 개선할 수 있다고 알려져 있다.Bromelain is a natural protein-decomposing enzyme found in abundance in the fruit and stem of pineapple. It enhances the effects of the digestive enzymes trypsin and pepsin to help digestion, and is combined with pancreatic juice to treat indigestion. Bromelain is absorbed in the small intestine and moves through the blood, dissolving fiber, protein, and impurities in the blood to purify the blood, while also promoting blood circulation, making it an effective ingredient for preventing heart disease. In addition, it is known to have excellent anti-inflammatory effects and can improve inflammation-related diseases such as arthritis, muscle pain, ligament damage, and sinusitis without side effects.
본 발명에서는 마황, 백출, 의이인, 숙지황, 인삼 및 맥문동을 포함하는 약재와 이용하여 전탕하고, 전탕한 전탕액과 상기 약재를 브로멜라인 분말과 혼합하여 제조되는 환을 제공하며, 상기 원료를 적용하여 우수한 다이어트 효과를 가지며, 동시에 디톡스 효과를 가진다.The present invention provides a pill manufactured by decocting medicinal ingredients including ephedra, white atractylodes, rhizome of Eucommia ulmoides, rehmannia glutinosa, ginseng and Ophiopogon japonicus, and mixing the decocted liquid and the medicinal ingredients with bromelain powder, thereby providing an excellent diet effect and a detox effect by applying the above raw materials.
또한, 상기 다이어트 환은,In addition, the above diet pills,
마황 44-48 중량부, 백출 9-13 중량부, 의이인 13-17 중량부, 숙지황 9-13 중량부, 인삼 9-13 중량부 및 맥문동 4-8 중량부를 혼합하여 제1 약재를 제조하고, 상기 제1 약재를 약포대에 넣어 제1 약포대를 제조하는 단계;A step of preparing a first herbal medicine by mixing 44-48 parts by weight of Ephedra, 9-13 parts by weight of White Chrysanthemum, 13-17 parts by weight of Euicorea japonica, 9-13 parts by weight of Rehmannia glutinosa, 9-13 parts by weight of Panax ginseng, and 4-8 parts by weight of Ophiopogon japonicus, and placing the first herbal medicine in a herbal medicine pouch to prepare a first herbal medicine pouch;
석고 10-14 중량부, 대황 9-13 중량부, 구기자 9-13 중량부, 반하 9-13 중량부, 당귀 9-13 중량부, 감초 9-13 중량부, 석창포 9-13 중량부, 복령 9-13 중량부 및 황기 9-13 중량부를 혼합하여 제2 약재를 제조하고, 상기 제2 약재를 약포대에 넣어 제2 약포대를 제조하는 단계;A step of preparing a second herbal medicine by mixing 10-14 parts by weight of gypsum, 9-13 parts by weight of rhubarb, 9-13 parts by weight of wolfberry, 9-13 parts by weight of pinellia, 9-13 parts by weight of angelica, 9-13 parts by weight of licorice, 9-13 parts by weight of Seokchangpo, 9-13 parts by weight of Poria cocos, and 9-13 parts by weight of Astragali, and placing the second herbal medicine in a herbal medicine pouch to prepare a second herbal medicine pouch;
상기 제1 약포대 및 상기 제2 약포대를 정제수를 포함하는 전탕기에 넣고, 138-142℃의 온도에서 160-200분 동안 전탕하는 단계;A step of placing the first and second herbal medicine bottles in a boiler containing purified water and boiling them at a temperature of 138-142°C for 160-200 minutes;
전탕 후, 제1 약포대 및 제2 약포대를 꺼내어 전탕액을 준비하고, 상기 전탕액을 농축하여 농축 전탕액을 제조하는 단계;After boiling, the first and second herbal medicine containers are taken out to prepare a boiling solution, and the boiling solution is concentrated to prepare a concentrated boiling solution;
꺼낸 제1 약포대의 제1 약재를 건조한 후 분쇄하여 제1 약재분말을 제조하는 단계; 및A step of drying and crushing the first medicinal herb from the first herbal medicine bag to produce the first medicinal herb powder; and
상기 제1 약재분말 78-82 중량부, 상기 농축 전탕액 8-12 중량부 및 브로멜라인 분말 8-12 중량부를 혼합하여 환을 제조하는 단계;를 수행하여 제조되는 것이 바람직하다.It is preferable to manufacture the pill by performing the step of mixing 78-82 parts by weight of the first herbal medicine powder, 8-12 parts by weight of the concentrated decoction, and 8-12 parts by weight of bromelain powder.
먼저, 마황 44-48 중량부, 백출 9-13 중량부, 의이인 13-17 중량부, 숙지황 9-13 중량부, 인삼 9-13 중량부 및 맥문동 4-8 중량부를 혼합하여 제1 약재를 제조하고, 상기 제1 약재를 약포대에 넣어 제1 약포대를 제조한다.First, the first herbal medicine is prepared by mixing 44-48 parts by weight of ephedra, 9-13 parts by weight of white atractylodes, 13-17 parts by weight of eucommia ulmoides, 9-13 parts by weight of rehmannia glutinosa, 9-13 parts by weight of ginseng, and 4-8 parts by weight of Ophiopogon japonicus, and the first herbal medicine is placed in a herbal medicine pouch to prepare the first herbal medicine pouch.
상기 제1 약포대는 제1 약재로 이루어지는 원료 자체를 환에 적용할 예정으로, 상기 비율로 제1 약재를 구성함으로써 우수한 다이어트 효과 및 디톡스 효과를 나타낸다.The above first herbal medicine container is intended to be applied to the pills as a raw material consisting of the first herbal medicine, and by composing the first herbal medicine in the above ratio, it exhibits excellent diet and detox effects.
다음, 석고 10-14 중량부, 대황 9-13 중량부, 구기자 9-13 중량부, 반하 9-13 중량부, 당귀 9-13 중량부, 감초 9-13 중량부, 석창포 9-13 중량부, 복령 9-13 중량부 및 황기 9-13 중량부를 혼합하여 제2 약재를 제조하고, 상기 제2 약재를 약포대에 넣어 제2 약포대를 제조한다.Next, 10-14 parts by weight of gypsum, 9-13 parts by weight of rhubarb, 9-13 parts by weight of wolfberry, 9-13 parts by weight of pinellia, 9-13 parts by weight of angelica, 9-13 parts by weight of licorice, 9-13 parts by weight of aconite, 9-13 parts by weight of poria, and 9-13 parts by weight of astragali are mixed to prepare a second herbal medicine, and the second herbal medicine is placed in a herbal medicine pouch to prepare a second herbal medicine pouch.
상기 제2 약포대는 제2 약재로 이루어지는 원료를 사용해 전탕액을 구성하는 것으로, 상기 비율로 제2 약재를 구성함으로써 우수한 다이어트 효과 및 디톡스 효과를 나타낸다.The above second herbal medicine container is made up of raw materials consisting of second medicinal herbs to form a decoction, and by forming the second medicinal herbs in the above ratio, it exhibits excellent diet and detox effects.
석고(石膏)란 황산칼슘의 이수화물로 이루어진 석회질로서 흔히 무색이지만 불순물이 섞이어 회색, 황색, 붉은색을 띠기도 한다. 열을 가하여 소석고로 사용하며 하얀돌가루로서, 한방에서는 청열제, 소염제, 해열에 사용한다.Gypsum is a limestone made of calcium sulfate dihydrate. It is usually colorless, but it can be gray, yellow, or red when mixed with impurities. It is used as calcined plaster when heated, and as white stone powder, it is used in oriental medicine as a fever-clearing agent, anti-inflammatory agent, and antipyretic.
대황(Eisenia bicyclis) 은 다시마목 감태과의 여러살이해 갈조식물로 대한민국의 울릉도, 독도 해역에 분포하며, 식약처에서 고시한 식품원재료에 전체부위가 식용가능부위로 명시되어 있다. 대황(Eisenia bicyclis)은 엑콜(eckol), 디엑콜(dieckol) 등과 같은 플로로탄닌(phlorotannin), 푸코스테롤(Fucosterol) 과 같은 스테롤(sterol), 다당류 , 피로페오피틴(pyropheophytin), 펩타이드(peptides), 옥실리핀(oxylipin) 등과 같은 생리활성성분이 보고된 바 있다. Eisenia bicyclis is a perennial brown algae belonging to the Laminariaceae family in the Laminaria order. It is distributed in the waters around Ulleungdo and Dokdo in South Korea. The entire plant is listed as edible in the food ingredients notified by the Ministry of Food and Drug Safety. Eisenia bicyclis has been reported to contain physiologically active components such as phlorotannins such as eckol and diekol, sterols such as fucosterol, polysaccharides, pyropheophytin, peptides, and oxylipins.
구기자는 가지과의 구기자잎속의 목본식물로 우리나라를 비롯한 중국, 대만, 일본, 유럽 등지에 자생하거나 재배되고 있는 생약재이다. 구기자는 열매, 잎, 뿌리를 부위별로 이용하며, 상기 구기자열매, 잎, 뿌리 등에는 베타인(betaine), 루틴(rutin), 쿠코아민 A(kukoamine A), 베타시토스테롤(-sitosterol)과 같은 기능성 성분이 다량 함유되어 있다. 그 밖에도 비타민 A, B1, B2, C 칼슘, 인, 철, 아연, 니코티닉산(nicotinic acid) 등 영양분을 풍부하게 함유하고 있다. 효능의 경우 피부의 색소 조절 효과에 대한 보고가 있다.Goji berry is a woody plant of the Lycium genus in the Solanaceae family, and is a medicinal herb native to or cultivated in Korea, China, Taiwan, Japan, and Europe. Goji berry is used for its fruit, leaves, and roots, and the goji berry fruit, leaves, and roots contain large amounts of functional ingredients such as betaine, rutin, kukoamine A, and beta-sitosterol. In addition, it contains abundant nutrients such as vitamins A, B1, B2, C, calcium, phosphorus, iron, zinc, and nicotinic acid. In terms of efficacy, there are reports of its effect in regulating skin pigmentation.
반하(Pinellia ternata)는 주피를 완전히 제거한 덩이줄기로 약간 눌려져 있는 구형이거나 불규칙한 구형이며, 지름 0.7~2.5cm, 높이 0.7~1.5cm이다. 바깥 면은 흰색 내지 회황백색이고 위쪽에는 줄기 자국이 오목하게 남아있으며 그 주변은 수염뿌리자국이 작은 점으로 촘촘하게 덮고 있다. 질은 충실하고 자르기 어렵다. 횡단면은 흰색이고 가루의 성질을 띄고, 냄새가 거의 없으며 맛은 처음에는 담담하고 약간 점액성이지만 후에 몹시 아리다.Pinellia ternata is a rhizome with the rhizome completely removed, slightly pressed, spherical or irregularly spherical, 0.7–2.5 cm in diameter, 0.7–1.5 cm in height. The outer surface is white or grayish white, and the upper part has concave stem marks, and the surrounding area is densely covered with small, dotted traces of beard roots. The quality is solid and difficult to cut. The cross-section is white, powdery, almost odorless, and the taste is initially bland and slightly mucilaginous, but later very bitter.
당귀(Angelica gigas)는 미나리과에 속하는 다년생 풀인 당귀의 뿌리를 말린 것으로, 맛은 달고 매우며 성질은 따뜻하다. 당귀의 효능에는 피가 부족할 때 피를 생성해주는 보혈작용이 있으며, 당귀는 관상동맥의 혈류량을 촉진시키고, 적혈구 생성을 왕성하게 한다.Angelica gigas is the dried root of Angelica gigas, a perennial plant in the parsley family. It has a sweet and very sweet taste and a warm nature. Angelica gigas has the effect of producing blood when there is a lack of blood, and it promotes blood flow in the coronary arteries and stimulates the production of red blood cells.
감초(Glycyrrhiza uralensis)는 콩과(Leguminosae)에 속하는 약용식물로 잘 알려져 있다. 현재까지 감초로부터 다양한 생물학적 활성 성분이 확인되었고, 주요 구성 요소로는 트리테르펜 사포닌(triterpene saponin), 플라보노이드(flavonoid) 등이 있다. 감초 및 감초의 활성 성분의 다양한 약리작용들이 보고되고 있다.Glycyrrhiza uralensis is a well-known medicinal plant belonging to the legume family (Leguminosae). Various biologically active components have been identified from Glycyrrhiza to date, and the main components include triterpene saponin and flavonoid. Various pharmacological actions of Glycyrrhiza and its active components have been reported.
석창포(Acorus gramineus Solander)는 한국, 중국, 일본을 포함한 동아시아에서 발견되며, 주로 뿌리줄기를 한약재로 사용하고 있고, 전통적으로 진정작용, 항경련 작용, 소화 촉진을 위하여 사용하고 있다. 석창포의 주요활성 성분은 β-asarone, α-asarone, phenylpropenes가 알려져 있으며 생리활성 리그난에 대한 연구도 진행되고 있다.Acorus gramineus Solander is found in East Asia including Korea, China, and Japan, and the rhizome is mainly used as a herbal medicine, and has been used traditionally for its sedative, antispasmodic, and digestive effects. The main active ingredients of Acorus gramineus are known to be β-asarone, α-asarone, and phenylpropenes, and research on physiologically active lignans is also being conducted.
복령은 한방에서 널리 쓰이는 생약으로 예로부터 도인들이 즐겨먹던 대표적인 양생법중의 하나로 전해진다. 중국 당나라 의학자 손진인이 저술한 '침중기'에는 "복령을 일백일만 먹으면 모든 병이 없어지고 이백일을 먹으면 밤낮으로 잠을 자지 않아도 피로나 괴로움을 느끼지 않으며, 3년을 계속 복용하면 귀신을 마음대로 부릴 수 있으며, 4년을 계속 복용하면 도인이 될 수 있다"라고 기재되어 있다.Poria cocos is a widely used herbal medicine in oriental medicine, and it has been said to be one of the representative health methods that Taoists have enjoyed since ancient times. In the "Sleep Record" written by Sun Jin-in, a physician from the Tang Dynasty in China, it is written that "if you eat Poria cocos for 100 days, all illnesses will disappear, if you eat it for 200 days, you will not feel tired or distressed even if you do not sleep day or night, if you continue to take it for 3 years, you will be able to control ghosts as you wish, and if you continue to take it for 4 years, you will become a Taoist."
황기(Astragalus membranaceus BUNGE)는 높이가 1m에 달하고 전체에 잔털이 있으며, 잎은 6∼11쌍의 소엽으로 구성된 기수1회우상복엽이다. 꽃은 7, 8월에 피고, 길이 15 ∼ 18 ㎜로서 연한 황색이며, 긴 꽃대에 여러 개의 꽃이 어긋나며 피는 꽃차례를 이룬다. 주로 뿌리를 약재로 사용하며, 동물실험에서는 중추신경계통의 흥분작용과 이뇨작용도 현저하였으며, 흰쥐에게 대량의 분말을 투여하였을 때에는 신염의 발생을 억제 시키고, 단백뇨와 콜레스테롤혈증의 발생도 지연시켰으며, 혈압강하작용도 인정되었다.Astragalus membranaceus BUNGE grows to 1 m tall, has fine hairs all over its body, and has odd-pinnate compound leaves composed of 6 to 11 pairs of leaflets. The flowers bloom in July and August, are 15 to 18 mm long, light yellow, and form inflorescences with multiple flowers blooming alternately on long flower stalks. The root is mainly used as a medicinal herb, and in animal experiments, it showed remarkable central nervous system stimulation and diuretic effects, and when a large amount of powder was administered to white rats, it suppressed the occurrence of nephritis, delayed the occurrence of proteinuria and cholesterolemia, and was also recognized as having a blood pressure-lowering effect.
본 발명에서는 상기 제1 약재와 상기 제2 약재를 이용해 전탕하고, 전탕한 전탕액과 상기 제2 약재가 포함된 전탕 과정을 통해 구성되는 상기 제1 약재를 적용한 환을 제공하며, 상기 원료를 적용하여 우수한 다이어트 효과를 가지며, 동시에 디톡스 효과를 가진다.The present invention provides a pill using the first herbal medicine and the second herbal medicine, which is made by boiling the first herbal medicine and the second herbal medicine through a boiling process including the boiled herbal medicine liquid and the second herbal medicine, and has an excellent diet effect by applying the raw material, and at the same time has a detox effect.
다음, 상기 제1 약포대 및 상기 제2 약포대를 정제수를 포함하는 전탕기에 넣고, 138-142℃의 온도에서 160-200분 동안 전탕한다. 상기 제1 약포대 48-52 중량부, 상기 제2 약포대 48-52 중량부 및 정제수 880-920 중량부를 전탕기에 넣는 것이 바람직하다.Next, the first and second herbal medicines are placed in a boiler containing purified water and boiled at a temperature of 138-142°C for 160-200 minutes. It is preferable to place 48-52 parts by weight of the first herbal medicine, 48-52 parts by weight of the second herbal medicine, and 880-920 parts by weight of purified water in the boiler.
다음, 전탕 후, 제1 약포대 및 제2 약포대를 꺼내어 전탕액을 준비하고, 상기 전탕액을 농축하여 농축 전탕액을 제조하는 단계를 포함한다.Next, after the boiling, the first and second herbal medicine containers are taken out to prepare a boiling solution, and the boiling solution is concentrated to produce a concentrated boiling solution.
상기 단계에서는 전탕 후, 제1 약포대와 제2 약포대를 꺼낸 전탕액을 이용해 농축하여 농축 전탕액을 제조한다. 상기 농축은 80-100 Brix의 당도를 가지도록 수행할 수 있다.In the above step, after boiling, the first and second herbal medicine containers are taken out and the boiling solution is concentrated to produce a concentrated boiling solution. The concentration can be performed to have a sugar content of 80-100 Brix.
다음, 꺼낸 제1 약포대의 제1 약재를 건조한 후 분쇄하여 제1 약재분말을 제조한다. 전탕 후 거낸 제1 약포대에 포함된 제1 약재를 건조한 후 분쇄하여 제1 약재분말을 제조한다. 제2 약포대는 제거한다. 상기 건조는 48-52℃의 온도에서 2-4시간 동안 수행할 수 있다.Next, the first herbal medicine in the first herbal medicine bag taken out is dried and then pulverized to produce the first herbal medicine powder. The first herbal medicine contained in the first herbal medicine bag taken out after boiling is dried and then pulverized to produce the first herbal medicine powder. The second herbal medicine bag is removed. The drying can be performed at a temperature of 48-52℃ for 2-4 hours.
다음, 상기 제1 약재분말 78-82 중량부, 상기 농축 전탕액 8-12 중량부 및 브로멜라인 분말 8-12 중량부를 혼합하여 환을 제조한다. 준비한 제1 약재분말과 농축 전탕액을 혼합하고, 여기에 브로멜라인 분말을 적용하여 환을 제조한다. 상기 환 제조는 일반적인 공정을 통해 성형 후 건조하여 제조할 수 있다.Next, 78-82 parts by weight of the first herbal powder, 8-12 parts by weight of the concentrated decoction, and 8-12 parts by weight of the bromelain powder are mixed to prepare pills. The prepared first herbal powder and the concentrated decoction are mixed, and the bromelain powder is applied thereto to prepare pills. The pills can be prepared by molding and then drying through a general process.
또한, 본 발명은In addition, the present invention
마황 44-48 중량부, 백출 9-13 중량부, 의이인 13-17 중량부, 숙지황 9-13 중량부, 인삼 9-13 중량부 및 맥문동 4-8 중량부를 혼합하여 제1 약재를 제조하고, 상기 제1 약재를 약포대에 넣어 제1 약포대를 제조하는 단계; 석고 10-14 중량부, 대황 9-13 중량부, 구기자 9-13 중량부, 반하 9-13 중량부, 당귀 9-13 중량부, 감초 9-13 중량부, 석창포 9-13 중량부, 복령 9-13 중량부 및 황기 9-13 중량부를 혼합하여 제2 약재를 제조하고, 상기 제2 약재를 약포대에 넣어 제2 약포대를 제조하는 단계; 상기 제1 약포대 및 상기 제2 약포대를 정제수를 포함하는 전탕기에 넣고, 138-142℃의 온도에서 160-200분 동안 전탕하는 단계; 전탕 후, 제1 약포대 및 제2 약포대를 꺼내어 전탕액을 준비하고, 상기 전탕액을 농축하여 농축 전탕액을 제조하는 단계; 및 꺼낸 제1 약포대의 제1 약재를 건조한 후 분쇄하여 제1 약재분말을 제조하는 단계;를 포함하는 농축 전탕액 및 제1 약재분말을 제조하는 단계;A step of preparing a first herbal medicine by mixing 44-48 parts by weight of Ephedra, 9-13 parts by weight of White Atractylodes, 13-17 parts by weight of Eui-in, 9-13 parts by weight of Rehmannia glutinosa, 9-13 parts by weight of Panax ginseng, and 4-8 parts by weight of Ophiopogon japonicus, and placing the first herbal medicine in a herbal medicine pouch to prepare a first herbal medicine pouch; A step of preparing a second herbal medicine by mixing 10-14 parts by weight of Gypsum, 9-13 parts by weight of Rhubarb, 9-13 parts by weight of Wolfberry, 9-13 parts by weight of Pinellia sinensis, 9-13 parts by weight of Angelica, 9-13 parts by weight of Glycyrrhiza uralensis, 9-13 parts by weight of Seokchangpo, 9-13 parts by weight of Poria cocos, and 9-13 parts by weight of Astragali, and placing the second herbal medicine in a herbal medicine pouch to prepare a second herbal medicine pouch; A step for preparing a concentrated decoction solution and a first herbal medicine powder, comprising the steps of: placing the first herbal medicine bag and the second herbal medicine bag in a boiler containing purified water, and boiling at a temperature of 138-142°C for 160-200 minutes; after boiling, taking out the first herbal medicine bag and the second herbal medicine bag to prepare a decoction solution, and concentrating the decoction solution to prepare a concentrated decoction solution; and drying and pulverizing the first herbal medicine in the taken out first herbal medicine bag to prepare a first herbal medicine powder;
견운모, 석영, 황옥, 맥반석 및 황토를 세척한 후, 분쇄하고 1:1:1:1:1의 중량비율로 혼합하여 광물분말을 제조하는 단계; 상기 광물분말 28-32 중량부 및 정제수 68-72 중량부를 혼합하여 광물혼합물을 제조하는 단계; 상기 광물혼합물을 118-122℃의 온도로 가열하여 5-7시간 동안 추출하는 단계; 가열 후 28-32℃의 온도에서 2-4일 동안 숙성하는 단계; 및 숙성 후 여과하여 여과액을 얻는 단계;를 포함하는 광물용액을 제조하는 단계;A step for preparing a mineral solution, comprising: a step of preparing a mineral powder by washing mite, quartz, topaz, feldspar, and yellow clay, grinding them, and mixing them in a weight ratio of 1:1:1:1:1; a step of preparing a mineral mixture by mixing 28-32 parts by weight of the mineral powder and 68-72 parts by weight of purified water; a step of heating the mineral mixture at a temperature of 118-122°C and extracting it for 5-7 hours; a step of maturing it at a temperature of 28-32°C for 2-4 days after the heating; and a step of filtering it after the maturation to obtain a filtrate;
자두나무잎, 동백나무잎 및 잣나무잎을 세척한 후, 58-62℃의 온도에서 2-4시간 동안 건조하는 단계; 건조한 자두나무잎, 동백나무잎 및 잣나무잎을 분쇄하고, 1:1:1의 중량비율로 혼합하여 잎분말을 제조하는 단계; 상기 잎분말 8-12 중량부 및 상기 광물용액 88-92 중량부를 혼합하고, 88-92℃의 온도에서 8-10시간 동안 추출하여 추출액을 제조하는 단계; 및 상기 추출액을 여과지로 여과하고, 여과된 여과액을 영하 48-52℃에서 감압농축 및 동결건조하는 단계;를 포함하는 천연식물 추출물을 제조하는 단계; 및A step for preparing a natural plant extract, comprising: a step of washing plum leaves, camellia leaves and pine leaves, and drying them at a temperature of 58-62°C for 2-4 hours; a step of grinding the dried plum leaves, camellia leaves and pine leaves, and mixing them at a weight ratio of 1:1:1 to prepare a leaf powder; a step of mixing 8-12 parts by weight of the leaf powder and 88-92 parts by weight of the mineral solution, and extracting them at a temperature of 88-92°C for 8-10 hours; and a step of filtering the extract through a filter paper, and subjecting the filtered filtrate to reduced pressure concentration and freeze-drying at -48-52°C; and
상기 제1 약재분말 58-62 중량부, 상기 천연식물 추출물 18-22 중량부, 상기 농축 전탕액 8-12 중량부 및 브로멜라인 분말 8-12 중량부를 혼합하여 환을 제조하는 단계;를 포함하는 다이어트 환의 제조방법을 제공한다.The present invention provides a method for manufacturing a diet pill, comprising the step of manufacturing a pill by mixing 58-62 parts by weight of the first herbal medicine powder, 18-22 parts by weight of the natural plant extract, 8-12 parts by weight of the concentrated decoction, and 8-12 parts by weight of bromelain powder.
이하, 본 발명에 따른 다이어트 환의 제조방법에 대하여 각 단계별로 상세히 설명한다.Hereinafter, the method for manufacturing a diet pill according to the present invention will be described in detail step by step.
먼저, 본 발명에 따른 다이어트 환의 제조방법은 농축 전탕액 및 제1 약재분말을 제조하는 단계를 포함한다. 상기 농축 전탕액 및 제1 약재분말을 제조하는 단계는, 마황 44-48 중량부, 백출 9-13 중량부, 의이인 13-17 중량부, 숙지황 9-13 중량부, 인삼 9-13 중량부 및 맥문동 4-8 중량부를 혼합하여 제1 약재를 제조하고, 상기 제1 약재를 약포대에 넣어 제1 약포대를 제조하는 단계; 석고 10-14 중량부, 대황 9-13 중량부, 구기자 9-13 중량부, 반하 9-13 중량부, 당귀 9-13 중량부, 감초 9-13 중량부, 석창포 9-13 중량부, 복령 9-13 중량부 및 황기 9-13 중량부를 혼합하여 제2 약재를 제조하고, 상기 제2 약재를 약포대에 넣어 제2 약포대를 제조하는 단계; 상기 제1 약포대 및 상기 제2 약포대를 정제수를 포함하는 전탕기에 넣고, 138-142℃의 온도에서 160-200분 동안 전탕하는 단계; 전탕 후, 제1 약포대 및 제2 약포대를 꺼내어 전탕액을 준비하고, 상기 전탕액을 농축하여 농축 전탕액을 제조하는 단계; 및 꺼낸 제1 약포대의 제1 약재를 건조한 후 분쇄하여 제1 약재분말을 제조하는 단계;를 포함한다.First, the method for manufacturing a diet pill according to the present invention includes a step of manufacturing a concentrated decoction and a first herbal medicine powder. The step of manufacturing the concentrated decoction and the first herbal medicine powder includes a step of mixing 44-48 parts by weight of Ephedra, 9-13 parts by weight of Baekchool, 13-17 parts by weight of Eui-in, 9-13 parts by weight of Rehmannia glutinosa, 9-13 parts by weight of Panax ginseng, and 4-8 parts by weight of Ophiopogon japonicus to manufacture the first herbal medicine, and putting the first herbal medicine in a herbal medicine pouch to manufacture the first herbal medicine pouch; The method includes: a step of mixing 10-14 parts by weight of gypsum, 9-13 parts by weight of rhubarb, 9-13 parts by weight of wolfberry, 9-13 parts by weight of pinellia, 9-13 parts by weight of angelica, 9-13 parts by weight of licorice, 9-13 parts by weight of Seokchangpo, 9-13 parts by weight of Poria cocos, and 9-13 parts by weight of Astragali to prepare a second herbal medicine, and placing the second herbal medicine in a herbal medicine pouch to prepare a second herbal medicine pouch; a step of putting the first herbal medicine pouch and the second herbal medicine pouch in a decoction vessel containing purified water, and boiling at a temperature of 138-142°C for 160-200 minutes; a step of taking out the first herbal medicine pouch and the second herbal medicine pouch to prepare a decoction liquid, and a step of concentrating the decoction liquid to prepare a concentrated decoction liquid; and a step of drying and pulverizing the first herbal medicine in the taken out first herbal medicine pouch to prepare a first herbal medicine powder.
상기 제1 약재분말 및 농축 전탕액을 제조하는 단계는 전술한 바와 같으므로 이하에서 상세한 설명을 생략한다. The steps for preparing the first herbal medicine powder and concentrated decoction are as described above, so a detailed description is omitted below.
다음으로, 본 발명에 따른 다이어트 환의 제조방법은 광물용액을 제조하는 단계를 포함한다. 상기 광물용액을 제조하는 단계는, 견운모, 석영, 황옥, 맥반석 및 황토를 세척한 후, 분쇄하고 1:1:1:1:1의 중량비율로 혼합하여 광물분말을 제조하는 단계; 상기 광물분말 28-32 중량부 및 정제수 68-72 중량부를 혼합하여 광물혼합물을 제조하는 단계; 상기 광물혼합물을 118-122℃의 온도로 가열하여 5-7시간 동안 추출하는 단계; 가열 후 28-32℃의 온도에서 2-4일 동안 숙성하는 단계; 및 숙성 후 여과하여 여과액을 얻는 단계;를 포함한다.Next, the method for manufacturing a diet pill according to the present invention includes a step of manufacturing a mineral solution. The step of manufacturing the mineral solution includes a step of manufacturing a mineral powder by washing and grinding mica, quartz, topaz, sphagnum moss, and yellow clay, and mixing them in a weight ratio of 1:1:1:1:1; a step of manufacturing a mineral mixture by mixing 28-32 parts by weight of the mineral powder and 68-72 parts by weight of purified water; a step of heating the mineral mixture to a temperature of 118-122°C and extracting it for 5-7 hours; a step of maturing it at a temperature of 28-32°C for 2-4 days after heating; and a step of filtering it after maturing to obtain a filtrate.
견운모는 유익한 미네랄을 다량 함유하고 있어 토양의 개량과 작물의 생육 촉진에 그 효과가 우수하고 높은 원적외선 방사 효과로 인하여 발아를 촉진하며, 토양 개량 효과 및 토양 중화 및 잔류 농약 제거 효과가 우수하여 농작물의 생산 증대와 건강한 먹거리 확보에 기여하는 것으로 알려져 있다.It is known that mica contains a large amount of beneficial minerals, so it is effective in improving soil and promoting crop growth. It also promotes germination due to its high far-infrared radiation effect, and it is excellent in improving soil, neutralizing soil, and removing residual pesticides, so it is known to contribute to increasing crop production and securing healthy food.
석영(quartz)은 육방정계에 속하는 광물로서, 화학성분은 SiO2이다. 조암광물의 대부분은 복잡한 고용체인데 반하여, 석영은 다른 성분이 거의 없어, 화학적으로 매우 순수하다. 주로 육각주상의 결정을 이루며, 괴상을 이루기도 하고, 때로는 입상(粒狀), 사상(砂狀)으로 산출되기도 하며, 다른 광물, 특히 방해석(方解石), 중정석(重晶石) 등의 가정(假晶)을 이루기도 한다. Quartz is a mineral belonging to the hexagonal crystal system, and its chemical composition is SiO2. While most rock-forming minerals are complex solid solutions, quartz has almost no other components, so it is chemically very pure. It mainly forms hexagonal crystals, and sometimes it occurs in a lump, granular, or sandy form, and it also forms pseudo-crystals of other minerals, especially calcite and barite.
황옥은 감람석과 같은 결정구조를 가지는 사방정계에 속하는 광물로 토파즈(topaz)라고도 한다. 황옥은 인간 신체에 필요한 칼슘, 철분 및 마그네슘을 함유하고 있어 원적외선 방사효과가 뛰어나고 천연 자기장을 통해 체내의 불필요한 노폐물을 제거하고 산성화된 혈액을 알칼리성으로 환원시켜 생체리듬을 활성화시킨다.Jade is a mineral belonging to the orthorhombic system with the same crystal structure as olivine, and is also called topaz. Jade contains calcium, iron, and magnesium necessary for the human body, and has an excellent far-infrared radiation effect. It removes unnecessary waste products from the body through natural magnetic fields, and turns acidified blood into alkaline, thereby activating the biorhythm.
맥반석은 무수규산(Sio2) 73,6%, 산화알미늄(AL2O3) 15,3%, 산화나트륨(NA2O) 3.44%, 산화마그네슘(MgO) 0.31%, 산화티타늄(TiO2) 0.17%, 산화제2철(Fe2O3) 1.71%, 산화칼륨(K2O) 4.43%, 산화몰리브텐(MnO) 0.05%의 성분을 이루어져, 1㎤당 3만 ~ 15만개의 다층다공질로 구성되어 있고 비 표면적이 넓어 오염물질, 중금속 등을 흡착, 분해하는 작용을 하며, 인체에 활력을 주는 40 여종 이상의 미네랄이 용출되어 신진대사와 피부건강관리에 효과가 있으며, 산성이나 강한 알칼리성 물을 약알칼리성(pH7.2 ~ 7.4)으로 조절하며, 수질을 활성화시켜 정수작용을 하고, 원적외선 방사에 의한 공명, 공진, 흡수작용 등으로 식품의 선도유지, 맛의 증가, 혈액순환 및 신진대사 촉진 등에 탁월한 효과가 있다.The stone is composed of 73.6% anhydrous silica (Sio2), 15.3% aluminum oxide (AL2O3), 3.44% sodium oxide (NA2O), 0.31% magnesium oxide (MgO), 0.17% titanium oxide (TiO2), 1.71% ferric oxide (Fe2O3), 4.43% potassium oxide (K2O), and 0.05% molybdenum oxide (MnO). It is composed of 30,000 to 150,000 multi-layer porous particles per 1㎤ and has a large specific surface area, so it has the effect of adsorbing and decomposing pollutants, heavy metals, etc., and more than 40 types of minerals that revitalize the human body are extracted, which are effective for metabolism and skin health management, and it adjusts acidic or strongly alkaline water to slightly alkaline (pH 7.2 to 7.4), activates water quality, and has a purifying effect, and emits far infrared rays. It has excellent effects in maintaining the freshness of food, increasing taste, and promoting blood circulation and metabolism through resonance, resonance, and absorption caused by radiation.
황토는 고대 한의학 경전에도 널리 그 효능이 수록되어 있는바, 인체의 적정체온을 유지시켜 주며, 모든 생물체의 각 신체부위를 균일하게 발달시킴과 동시에 빠른 성장효과를 주며, 이온 작용으로 체내에 칼슘 및 철분영양의 균형을 이루어 뼈를 튼튼하게 할 뿐만 아니라, 신체의 적정 수분을 유지시켜주며, 체내의 노폐물을 배출시켜 주고 인체의 지방질, 단백질 및 탄수화물의 영양을 분해하여 균형있게 유지시키고 세포의 분자와 원자를 진동시켜 강인한 체력을 가지게 하는 등의 효과를 보여준다.The efficacy of loess is widely recorded in ancient Oriental medical scriptures. It maintains the body's appropriate temperature, promotes even development of each body part of all living things while providing a rapid growth effect, and strengthens bones by creating a nutritional balance of calcium and iron in the body through ion action. It also maintains the body's appropriate moisture level, discharges waste products from the body, breaks down and balances the nutrition of fat, protein, and carbohydrates in the body, and vibrates the molecules and atoms of cells to provide strong physical strength.
상기 광물용액은 견운모, 석영, 황옥, 맥반석 및 황토를 이용하여 추출한 용액으로, 이는 과량의 미네랄을 함유하게 되며, 이러한 미네랄 함유 광물용액을 이용해 천연식물인 자두나무잎, 동백나무잎 및 잣나무잎으로부터 추출물을 제조함으로써 우수한 항산화 기능성, 항염 기능성, 다이어트 효과 및 디톡스 효과를 확보할 수 있다.The above mineral solution is a solution extracted using mica, quartz, topaz, feldspar and yellow clay, which contains an excessive amount of minerals. By using this mineral-containing mineral solution to manufacture extracts from natural plants such as plum leaves, camellia leaves and pine leaves, excellent antioxidant functionality, anti-inflammatory functionality, diet effect and detox effect can be secured.
다음으로, 본 발명에 따른 다이어트 환의 제조방법은 천연식물 추출물을 제조하는 단계를 포함한다. 상기 천연식물 추출물을 제조하는 단계는, 자두나무잎, 동백나무잎 및 잣나무잎을 세척한 후, 58-62℃의 온도에서 2-4시간 동안 건조하는 단계; 건조한 자두나무잎, 동백나무잎 및 잣나무잎을 분쇄하고, 1:1:1의 중량비율로 혼합하여 잎분말을 제조하는 단계; 상기 잎분말 8-12 중량부 및 상기 광물용액 88-92 중량부를 혼합하고, 88-92℃의 온도에서 8-10시간 동안 추출하여 추출액을 제조하는 단계; 및 상기 추출액을 여과지로 여과하고, 여과된 여과액을 영하 48-52℃에서 감압농축 및 동결건조하는 단계;를 포함한다.Next, the method for manufacturing a diet pill according to the present invention includes a step of manufacturing a natural plant extract. The step of manufacturing the natural plant extract includes a step of washing plum leaves, camellia leaves, and pine leaves, and drying them at a temperature of 58-62°C for 2-4 hours; a step of grinding the dried plum leaves, camellia leaves, and pine leaves, and mixing them at a weight ratio of 1:1:1 to manufacture a leaf powder; a step of mixing 8-12 parts by weight of the leaf powder and 88-92 parts by weight of the mineral solution, and extracting them at a temperature of 88-92°C for 8-10 hours to manufacture an extract; and a step of filtering the extract through a filter paper, and a step of subjecting the filtered filtrate to reduced pressure concentration and freeze-drying at -48-52°C.
자두나무(Prunus salicina)는 한국, 중국에 분포하고 있으며 원산지는 중국인 나무이다. 생물학적 분류로는 과는 장미과(Rosaceae), 속은 Prunus 에 속하며 크기는 보통 10M에 달하며 개화 시기는 4월, 수확 시기는 6~7월이며 꽃말은 순백, 순박이다. 잎은 어긋나며 달걀꼴 또는 타원상 긴 달걀모양이고 급한 점첨두(漸尖頭)이며 예저(銳底)이고 길이 5∼10㎝, 너비 2∼4㎝로서 가장자리에 둔한 톱니가 있거나 복거치가 있다. Prunus salicina is distributed in Korea and China, and is a tree native to China. Biologically, the family is Rosaceae, the genus is Prunus, the size usually reaches 10 m, the flowering season is April, the harvest season is June~July, and the flower language is pure white, pure plum. The leaves are opposite, ovate or ovate-elliptic, with an acute acuminate head and a blunt base, 5~10 cm long, 2~4 cm wide, and have dull serrations or serrate margins.
동백나무는 나무는 숯으로, 열매는 기름으로, 꽃과 잎은 약으로 쓰인다. 여기서, 동백나무잎(Cameljia Japonica Leaf)은 토혈, 혈붕, 장충하혈, 혈리, 건선(乾癬), 인후통증(咽喉痛症), 화상(火傷), 혈액순환에 효능이 있고, 항균 기능이 있는 것으로 알려져 있다. Camellia tree wood is used as charcoal, fruit is used as oil, and flowers and leaves are used as medicine. Here, Cameljia Japonica Leaf is known to be effective for hemoptysis, hematuria, hematuria, hematuria, psoriasis, sore throat, burns, blood circulation, and has antibacterial properties.
잣나무(Pinus koraiensis Siebold et Zuccarini)는 소나무과에 속하는 상록 교목으로 우리나라 전국에 분포되어 있고 만주, 흑룡강 유역, 일본(북해도 제외)등에 분포되어 있다. 잎이 솔잎과 비슷하나 좀 더 푸르고 굵다. 높이는 10 내지 30 m나 자라며 나무껍질은 회갈색인데 묵으면 비늘 모양이 되어 떨어진다.Korean pine (Pinus koraiensis Siebold et Zuccarini) is an evergreen tree in the pine family. It is distributed throughout Korea, Manchuria, the Heilongjiang River basin, and Japan (except Hokkaido). Its leaves are similar to pine needles, but are greener and thicker. It grows to a height of 10 to 30 m, and its bark is gray-brown, but when old, it becomes scale-like and falls off.
미네랄 함유 광물용액을 이용해 천연식물인 자두나무잎, 동백나무잎 및 잣나무잎으로부터 추출물을 제조함으로써 우수한 항산화 기능성, 항염 기능성, 다이어트 효과 및 디톡스 효과를 확보할 수 있다.By manufacturing extracts from natural plants such as plum leaves, camellia leaves, and pine leaves using mineral-containing mineral solutions, excellent antioxidant functionality, anti-inflammatory functionality, diet effect, and detox effect can be secured.
다음으로, 본 발명에 따른 다이어트 환의 제조방법은 상기 제1 약재분말 58-62 중량부, 상기 천연식물 추출물 18-22 중량부, 상기 농축 전탕액 8-12 중량부 및 브로멜라인 분말 8-12 중량부를 혼합하여 환을 제조하는 단계를 포함한다.Next, the method for manufacturing a diet pill according to the present invention includes a step of manufacturing a pill by mixing 58-62 parts by weight of the first herbal medicine powder, 18-22 parts by weight of the natural plant extract, 8-12 parts by weight of the concentrated decoction, and 8-12 parts by weight of bromelain powder.
상기 단계에서는 준비한 제1 약재분말, 천연식물 추출물, 농축 전탕액 및 브로멜라인 분말을 이용해 환을 제조한다.In the above step, pills are made using the prepared first herbal powder, natural plant extract, concentrated decoction, and bromelain powder.
이하, 본 발명을 하기의 실시예에 의해 보다 상세하게 설명한다.Hereinafter, the present invention will be described in more detail by the following examples.
단, 하기 실시예는 본 발명의 내용을 예시하는 것일 뿐 발명의 범위가 실시예 및 실험예에 의해 한정되는 것은 아니다.However, the following examples are only intended to illustrate the content of the present invention, and the scope of the invention is not limited by the examples and experimental examples.
<실시예 1> 다이어트 환의 제조-1<Example 1> Manufacturing of diet pills-1
마황 46 중량부, 백출 11 중량부, 의이인 15 중량부, 숙지황 11 중량부, 인삼 11 중량부 및 맥문동 6 중량부를 혼합하여 제1 약재를 제조하고, 상기 제1 약재를 약포대에 넣어 제1 약포대를 제조하였다. 상기 제1 약포대 100 중량부 및 정제수 900 중량부를 전탕기에 넣고, 140℃의 온도에서 180분 동안 전탕하였다. 전탕 후, 제1 약포대를 꺼내어 전탕액을 준비하고, 상기 전탕액을 100 Brix의 농도로 농축하여 농축 전탕액을 제조하였다. 제1 약포대의 제1 약재를 50℃의 온도에서 3시간 동안 건조한 후 분쇄하여 제1 약재분말을 제조하였다.The first herbal medicine was prepared by mixing 46 parts by weight of Ma-hwang, 11 parts by weight of Baek-chool, 15 parts by weight of Eui-in, 11 parts by weight of Rehmannia glutinosa, 11 parts by weight of Panax ginseng, and 6 parts by weight of Ophiopogon japonicus, and the first herbal medicine was placed in a herbal medicine container to prepare a first herbal medicine container. 100 parts by weight of the first herbal medicine container and 900 parts by weight of purified water were placed in a boiler and boiled at 140°C for 180 minutes. After boiling, the first herbal medicine container was taken out to prepare a boiling solution, and the boiling solution was concentrated to a concentration of 100 Brix to prepare a concentrated boiling solution. The first herbal medicine in the first herbal medicine container was dried at 50°C for 3 hours and then pulverized to prepare a first herbal medicine powder.
상기 제1 약재분말 80 중량부, 상기 농축 전탕액 10 중량부 및 브로멜라인 분말 10 중량부를 혼합하여 성형 및 건조하여 다이어트 환을 제조하였다.80 parts by weight of the above first medicinal herb powder, 10 parts by weight of the above concentrated decoction, and 10 parts by weight of bromelain powder were mixed, molded, and dried to produce a diet pill.
<실시예 2> 다이어트 환의 제조-2<Example 2> Manufacturing of diet pills-2
마황 46 중량부, 백출 11 중량부, 의이인 15 중량부, 숙지황 11 중량부, 인삼 11 중량부 및 맥문동 6 중량부를 혼합하여 제1 약재를 제조하고, 상기 제1 약재를 약포대에 넣어 제1 약포대를 제조하였다. 석고 12 중량부, 대황 11 중량부, 구기자 11 중량부, 반하 11 중량부, 당귀 11 중량부, 감초 11 중량부, 석창포 11 중량부, 복령 11 중량부 및 황기 11 중량부를 혼합하여 제2 약재를 제조하고, 상기 제2 약재를 약포대에 넣어 제2 약포대를 제조하였다. 상기 제1 약포대 50 중량부, 상기 제2 약포대 50 중량부 및 정제수 900 중량부를 전탕기에 넣고, 140℃의 온도에서 180분 동안 전탕하였다. 전탕 후, 제1 약포대와 제2 약포대를 모두 꺼내어 전탕액을 준비하고, 상기 전탕액을 100 Brix의 농도로 농축하여 농축 전탕액을 제조하였다. 제1 약포대의 제1 약재를 50℃의 온도에서 3시간 동안 건조한 후 분쇄하여 제1 약재분말을 제조하였다.A first herbal medicine was prepared by mixing 46 parts by weight of Ma-hwang, 11 parts by weight of Baek-chool, 15 parts by weight of Eui-in, 11 parts by weight of Rehmannia glutinosa, 11 parts by weight of Panax ginseng, and 6 parts by weight of Ophiopogon japonicus, and the first herbal medicine was placed in a herbal medicine bag to prepare a first herbal medicine bag. A second herbal medicine was prepared by mixing 12 parts by weight of Gypsum, 11 parts by weight of Rhubarb, 11 parts by weight of Wolfberry, 11 parts by weight of Pinellia sinensis, 11 parts by weight of Angelica, 11 parts by weight of Glycyrrhiza uralensis, 11 parts by weight of Seok-chang-po, 11 parts by weight of Poria cocos, and 11 parts by weight of Astragali, and the second herbal medicine was placed in a herbal medicine bag to prepare a second herbal medicine bag. 50 parts by weight of the first herbal medicine bag, 50 parts by weight of the second herbal medicine bag, and 900 parts by weight of purified water were placed in a boiler and boiled at a temperature of 140℃ for 180 minutes. After the decoction, both the first and second herbal containers were taken out to prepare a decoction solution, and the decoction solution was concentrated to a concentration of 100 Brix to prepare a concentrated decoction solution. The first herbal medicine in the first herbal container was dried at a temperature of 50℃ for 3 hours and then pulverized to prepare a first herbal medicine powder.
상기 제1 약재분말 80 중량부, 상기 농축 전탕액 10 중량부 및 브로멜라인 분말 10 중량부를 혼합하여 성형 및 건조하여 다이어트 환을 제조하였다.80 parts by weight of the above first medicinal herb powder, 10 parts by weight of the above concentrated decoction, and 10 parts by weight of bromelain powder were mixed, molded, and dried to produce a diet pill.
<실시예 3> 다이어트 환의 제조-3<Example 3> Manufacturing of diet pills-3
마황 46 중량부, 백출 11 중량부, 의이인 15 중량부, 숙지황 11 중량부, 인삼 11 중량부 및 맥문동 6 중량부를 혼합하여 제1 약재를 제조하고, 상기 제1 약재를 약포대에 넣어 제1 약포대를 제조하였다. 석고 12 중량부, 대황 11 중량부, 구기자 11 중량부, 반하 11 중량부, 당귀 11 중량부, 감초 11 중량부, 석창포 11 중량부, 복령 11 중량부 및 황기 11 중량부를 혼합하여 제2 약재를 제조하고, 상기 제2 약재를 약포대에 넣어 제2 약포대를 제조하였다. 상기 제1 약포대 50 중량부, 상기 제2 약포대 50 중량부 및 정제수 900 중량부를 전탕기에 넣고, 140℃의 온도에서 180분 동안 전탕하였다. 전탕 후, 제1 약포대와 제2 약포대를 모두 꺼내어 전탕액을 준비하고, 상기 전탕액을 100 Brix의 농도로 농축하여 농축 전탕액을 제조하였다. 제1 약포대의 제1 약재를 50℃의 온도에서 3시간 동안 건조한 후 분쇄하여 제1 약재분말을 제조하였다.A first herbal medicine was prepared by mixing 46 parts by weight of Ma-hwang, 11 parts by weight of Baek-chool, 15 parts by weight of Eui-in, 11 parts by weight of Rehmannia glutinosa, 11 parts by weight of Panax ginseng, and 6 parts by weight of Ophiopogon japonicus, and the first herbal medicine was placed in a herbal medicine bag to prepare a first herbal medicine bag. A second herbal medicine was prepared by mixing 12 parts by weight of Gypsum, 11 parts by weight of Rhubarb, 11 parts by weight of Wolfberry, 11 parts by weight of Pinellia sinensis, 11 parts by weight of Angelica, 11 parts by weight of Glycyrrhiza uralensis, 11 parts by weight of Seok-chang-po, 11 parts by weight of Poria cocos, and 11 parts by weight of Astragali, and the second herbal medicine was placed in a herbal medicine bag to prepare a second herbal medicine bag. 50 parts by weight of the first herbal medicine bag, 50 parts by weight of the second herbal medicine bag, and 900 parts by weight of purified water were placed in a boiler and boiled at a temperature of 140℃ for 180 minutes. After the decoction, both the first and second herbal containers were taken out to prepare a decoction solution, and the decoction solution was concentrated to a concentration of 100 Brix to prepare a concentrated decoction solution. The first herbal medicine in the first herbal container was dried at a temperature of 50℃ for 3 hours and then pulverized to prepare a first herbal medicine powder.
견운모, 석영, 황옥, 맥반석 및 황토를 세척한 후, 분쇄하고 1:1:1:1:1의 중량비율로 혼합한 광물분말 30 중량부 및 정제수 70 중량부를 혼합하여 광물혼합물을 제조하고, 120℃의 온도로 가열하여 6시간 동안 추출하였다. 가열 후 30℃의 온도에서 3일 동안 숙성하고, 숙성 후 여과하여 광물용액을 제조하였다.After washing and crushing mite, quartz, topaz, feldspar and yellow clay, 30 parts by weight of mineral powders mixed in a weight ratio of 1:1:1:1:1 and 70 parts by weight of purified water were mixed to prepare a mineral mixture, heated to a temperature of 120℃ and extracted for 6 hours. After heating, it was aged at a temperature of 30℃ for 3 days, and after aging, it was filtered to prepare a mineral solution.
자두나무잎, 동백나무잎 및 잣나무잎을 세척한 후, 60℃의 온도에서 3시간 동안 건조하고, 분쇄하고, 1:1:1의 중량비율로 혼합하여 잎분말을 제조하였다. 상기 잎분말 10 중량부 및 상기 광물용액 90 중량부를 혼합하고, 90℃의 온도에서 9시간 동안 추출하여 추출액을 제조하였다. 상기 추출액을 여과지로 여과하고, 여과된 여과액을 영하 50℃에서 감압농축 및 동결건조하여 천연식물 추출물을 제조하였다.Plum leaves, camellia leaves and pine leaves were washed, dried at 60°C for 3 hours, pulverized and mixed in a weight ratio of 1:1:1 to prepare a leaf powder. 10 parts by weight of the leaf powder and 90 parts by weight of the mineral solution were mixed and extracted at 90°C for 9 hours to prepare an extract. The extract was filtered through a filter paper, and the filtered filtrate was concentrated under reduced pressure at -50°C and freeze-dried to prepare a natural plant extract.
상기 제1 약재분말 60 중량부, 상기 천연식물 추출물 20 중량부, 상기 농축 전탕액 10 중량부 및 브로멜라인 분말 10 중량부를 혼합하여 성형 및 건조하여 다이어트 환을 제조하였다.60 parts by weight of the above first medicinal herb powder, 20 parts by weight of the above natural plant extract, 10 parts by weight of the above concentrated decoction, and 10 parts by weight of bromelain powder were mixed, molded, and dried to produce a diet pill.
<실험예 1> 다이어트 효과 분석<Experimental Example 1> Analysis of diet effects
상기 실시예 1-3에서 제조한 다이어트 환에 대하여 다이어트 효과를 확인하기 위하여 아래와 같은 실험을 수행하였다. In order to confirm the diet effect of the diet pills manufactured in Examples 1-3 above, the following experiment was conducted.
실험식이는 흰쥐용 일반 고형사료(AIN-93G)를 기본식이(basal diet)로 하여 대조군으로는 기본식이에 돈지(lard)와 콜레스테롤을 각각 7%, 1%씩 중량비(weight basis)로 첨가하여 식이중의 총 지방함량이 약 15%가 되도록 제조한 고지방식이를 10주 동안 급여하였고, 실험군으로는 6주 동안 대조군과 동일하게 고지방식이한 후, 동일한 고지방식이에 각각 실시예 1-3의 다이어트 환을 분쇄하여을 각각 3%씩 중량비로 첨가한 실험식이를 4주간 급여하였다. The experimental diet consisted of a general solid feed for rats (AIN-93G) as the basal diet, and the control group was fed a high-fat diet prepared by adding 7% lard and 1% cholesterol on a weight basis to the basal diet so that the total fat content of the diet was approximately 15% for 10 weeks. The experimental group was fed the same high-fat diet as the control group for 6 weeks, and then fed an experimental diet in which the crushed diet pills of Examples 1-3 were each added on a weight basis at a weight basis of 3% each for 4 weeks.
실험동물은 3주령 된 Sprague-Dawley(SD)계 수컷 흰쥐를 (주)한림실험동물(Hwaseong, Gyeonggi, Korea)에서 구입하였고, 실험 전 1주일 동안 흰쥐용 일반 고형사료로 적응기를 거친 후 난괴법(randomized block design)으로 각 처리군당 10마리씩 임의배치 하여 케이지당 2마리씩 총 10주간 사육하였다. 사육실의 환경은 항온(23±1℃) 및 항습(50±5%)조건을 유지하였고, 조명은 12시간 light/dark cycle(08:00-20:00)로 일정하게 조절하였다. 실험기간 동안 식이와 식수는 자유섭취(ad libitum)하도록 하였고, 체중은 1주일에 한 번씩 일정한 시간에 실험동물저울(GF-2000, AND, Anyang, Gyeonggi, Korea)을 이용하여 측정하였으며, 식이섭취량은 매일 일정한 시간에 공급하고 남은 식이를 4℃에서 냉장보관 한 후 1주일에 한 번 측정하였다. 식이효율(feed efficiency ratio, FER)은 체중증가량을 동일 기간 동안의 식이섭취량으로 나누어 계산하였다. 실험군 간 유의성 검정은 ANOVA test 후 Duncan's multiple range test로 p<0.05 수준에서 검정하였다. 그 결과를 하기 표 1에 나타내었다.Experimental animals were 3-week-old male Sprague-Dawley (SD) rats purchased from Hanlim Laboratory Animal Co., Ltd. (Hwaseong, Gyeonggi, Korea). After an adaptation period of 1 week with general solid rat food prior to the experiment, 10 rats were randomly assigned to each treatment group using a randomized block design and were raised with 2 rats per cage for a total of 10 weeks. The rearing room environment was maintained at constant temperature (23±1℃) and humidity (50±5%), and lighting was constantly controlled with a 12-h light/dark cycle (08:00-20:00). During the experimental period, food and water were provided ad libitum. Body weight was measured once a week at a set time using a laboratory animal scale (GF-2000, AND, Anyang, Gyeonggi, Korea). Food intake was supplied at a set time every day, and the remaining food was refrigerated at 4℃ and measured once a week. The feed efficiency ratio (FER) was calculated by dividing the body weight gain by the food intake during the same period. The significance between the experimental groups was tested at the p<0.05 level using the ANOVA test followed by Duncan's multiple range test. The results are shown in Table 1 below.
(g)Starting weight (6 weeks)
(g)
(g)End weight (10 weeks)
(g)
일당증체량
(g/day)4 weeks
Daily weight gain
(g/day)
식이섭취량
(g/day)4 weeks
Dietary intake
(g/day)
식이효율
(FER)4 weeks
Dietary efficiency
(FER)
상기 표 1에 나타낸 바와 같이, 본 발명에 따른 다이어트 환을 적용하는 경우 우수한 다이어트 효과가 있음을 확인할 수 있었다.As shown in Table 1 above, it was confirmed that an excellent diet effect was achieved when the diet ring according to the present invention was applied.
<실험예 2> 디톡스 효과 분석<Experimental Example 2> Detox Effect Analysis
상기 실시예 1-3에서 제조한 다이어트 환에 대하여 디톡스 효과를 확인하기 위하여 상기 실험예 1에서 사용하여 실험종료한 실험동물을 이용해 혈액의 성분을 분석하였다. 정상군으로 일반적인 정상 식이를 공급하여 실험을 수행하였다. 혈액의 생화학적 분석을 위한 혈청분석 항목은 총 콜레스테롤, 중성지방, GOT(glutamic oxaloacetic transaminase), GPT(glutamic-pyruvic transaminase), BUN(blood urea nitrogen)으로, 자동혈액분석기(ModulaAnalytics, Roche)로 분석하였으며, 내독소의 측청은 PierceLAL Chromogenic Endotoxin Quantitation Kit(Thermo Scientific., USA)를 이용하여 제조사의 방법으로 분석하였으며, 그 결과를 하기의 표 2에 나타내었다.In order to confirm the detox effect of the diet pills manufactured in the above Examples 1-3, blood components were analyzed using experimental animals that had completed the experiment in the above Experimental Example 1. The experiment was conducted by feeding a general normal diet to the normal group. The serum analysis items for biochemical analysis of blood were total cholesterol, neutral fat, GOT (glutamic oxaloacetic transaminase), GPT (glutamic-pyruvic transaminase), and BUN (blood urea nitrogen), and were analyzed using an automatic blood analyzer (ModulaAnalytics, Roche). The endotoxin was measured using a PierceLAL Chromogenic Endotoxin Quantitation Kit (Thermo Scientific., USA) according to the manufacturer's method, and the results are shown in Table 2 below.
상기 표 4에 나타낸 바와 같이, 본 발명에 따른 다이어트 환을 적용하는 경우 혈중 내독소 함량이 감소하여 디톡스 효과가 있음을 확인할 수 있었다.As shown in Table 4 above, it was confirmed that when the diet pill according to the present invention was applied, the blood endotoxin content was reduced, thereby showing a detox effect.
<실험예 3> 항산화 기능성 분석<Experimental Example 3> Antioxidant Functional Analysis
상기 실시예 1-3에서 제조한 다이어트 환을 시료로 하여 항산화력을 DPPH(2,2-Diphenyl-1-picryl-hydrazyl)라디칼 소거 활성으로 측정하였다. DPPH 라디칼 소거능은 Mensor 등의 방법을 참고하였다. 80㎕의 0.2mM DPPH 에탄올 용액을 각 시료에 20㎕ 가한 후 1분간 교반한 후 25℃ 인큐베이터에서 10분간 반응시켜 ELISA reader를 사용하여 517nm에서 흡광도를 측정하였다. DPPH 라디칼 소거활성은 하기 계산식 1에 따라 백분율로 나타내었으며 그 결과를 하기 표 3에 나타내었다.The antioxidant activity of the diet pills manufactured in the above Examples 1-3 was measured by DPPH (2,2-Diphenyl-1-picryl-hydrazyl) radical scavenging activity. The DPPH radical scavenging activity was measured by referring to the method of Mensor et al. 20 ㎕ of 80 ㎕ of 0.2 mM DPPH ethanol solution was added to each sample, stirred for 1 minute, reacted for 10 minutes in an incubator at 25℃, and measured for absorbance at 517 nm using an ELISA reader. The DPPH radical scavenging activity was expressed as a percentage according to the following calculation formula 1, and the results are shown in Table 3 below.
<계산식 1><Calculation formula 1>
상기 표 3에서 나타낸 바와 같이, 본 발명에 따른 다이어트 환은 높은 DPPH 라디칼 소거활성 수치값이 측정되었으며, 우수한 항산화 기능성을 가짐을 확인할 수 있다.As shown in Table 3 above, the diet pill according to the present invention was measured to have a high DPPH radical scavenging activity value, confirming that it has excellent antioxidant functionality.
<실험예 4> 항염 기능성 분석<Experimental Example 4> Anti-inflammatory functional analysis
상기 실시예 1-3에서 제조한 다이어트 환을 시료로 하여 염증 유발에 중요한 역할을 하는 것으로 알려진 NO(Nitric Oxide) 생성 억제에 대한 효과를 확인하였다. 일반적인 NO의 형성은 박테리아를 죽이거나 종양을 제거시키는 중요한 역할을 하지만, 염증상태에서 iNOS에 의해 생성된 NO는 혈관 투과성, 부종 등의 염증반응을 촉진시킬 뿐만 아니라 염증매개체의 생합성을 촉진하여 염증을 심화시키는 것으로 알려져 있다.Raw 264.7 세포를 10% 륜가 첨가된 DMEM 배지를 이용하여 5×105 cell/well로 조절한 후 24 well plate에 접종하고, 시료를 처리하고 30분 배양 후 LPS(Lipopolysaccharide, 1㎍/㎖)를 첨가하여 24시간 배양하였다. 생성된 NO의 양은 NO 검출키트(iNtRON)를 이용한 측정값을 하기 계산식 2에 의해 산출하고 대조군은 LPS를 단독으로 처리한 실험군이다. NO 생성 억제율 결과는 하기 표 4에 나타내었다.The effect of inhibiting the production of NO (Nitric Oxide), which is known to play an important role in inducing inflammation, was confirmed using the diet pills manufactured in the above Examples 1-3 as samples. The formation of general NO plays an important role in killing bacteria or removing tumors, but NO produced by iNOS in an inflammatory state is known to promote inflammatory responses such as vascular permeability and edema, as well as promote the biosynthesis of inflammatory mediators, thereby aggravating inflammation. Raw 264.7 cells were adjusted to 5 × 10 5 cells/well using DMEM medium supplemented with 10% chloroform, and then inoculated into a 24-well plate. After treating the sample and incubating for 30 minutes, LPS (Lipopolysaccharide, 1 ㎍/㎖) was added and incubated for 24 hours. The amount of NO produced was calculated using the measurement value using a NO detection kit (iNtRON) using the following calculation formula 2, and the control group is an experimental group treated with LPS alone. The results of the NO production inhibition rate are shown in Table 4 below.
<계산식 2><Calculation formula 2>
상기 표 4에서 나타낸 바와 같이, 본 발명에 따른 다이어트 환은 매우 높은 NO 생성 억제율을 나타내었으며, 우수한 항염 효과가 나타내는 것을 확인할 수 있다.As shown in Table 4 above, the diet pill according to the present invention showed a very high NO production inhibition rate, and it was confirmed that it showed an excellent anti-inflammatory effect.
Claims (3)
견운모, 석영, 황옥, 맥반석 및 황토를 세척한 후, 분쇄하고 1:1:1:1:1의 중량비율로 혼합하여 광물분말을 제조하는 단계; 상기 광물분말 28-32 중량부 및 정제수 68-72 중량부를 혼합하여 광물혼합물을 제조하는 단계; 상기 광물혼합물을 118-122℃의 온도로 가열하여 5-7시간 동안 추출하는 단계; 가열 후 28-32℃의 온도에서 2-4일 동안 숙성하는 단계; 및 숙성 후 여과하여 여과액을 얻는 단계;를 포함하는 광물용액을 제조하는 단계;
자두나무잎, 동백나무잎 및 잣나무잎을 세척한 후, 58-62℃의 온도에서 2-4시간 동안 건조하는 단계; 건조한 자두나무잎, 동백나무잎 및 잣나무잎을 분쇄하고, 1:1:1의 중량비율로 혼합하여 잎분말을 제조하는 단계; 상기 잎분말 8-12 중량부 및 상기 광물용액 88-92 중량부를 혼합하고, 88-92℃의 온도에서 8-10시간 동안 추출하여 추출액을 제조하는 단계; 및 상기 추출액을 여과지로 여과하고, 여과된 여과액을 영하 48-52℃에서 감압농축 및 동결건조하는 단계;를 포함하는 천연식물 추출물을 제조하는 단계; 및
상기 제1 약재분말 58-62 중량부, 상기 천연식물 추출물 18-22 중량부, 상기 농축 전탕액 8-12 중량부 및 브로멜라인 분말 8-12 중량부를 혼합하여 환을 제조하는 단계;를 포함하는 비만 예방 또는 치료용 약학적 조성물의 제조방법.A step of preparing a first herbal medicine by mixing 44-48 parts by weight of Ephedra, 9-13 parts by weight of White Atractylodes, 13-17 parts by weight of Eui-in, 9-13 parts by weight of Rehmannia glutinosa, 9-13 parts by weight of Panax ginseng, and 4-8 parts by weight of Ophiopogon japonicus, and placing the first herbal medicine in a herbal medicine pouch to prepare a first herbal medicine pouch; A step of preparing a second herbal medicine by mixing 10-14 parts by weight of Gypsum, 9-13 parts by weight of Rhubarb, 9-13 parts by weight of Wolfberry, 9-13 parts by weight of Pinellia sinensis, 9-13 parts by weight of Angelica, 9-13 parts by weight of Glycyrrhiza uralensis, 9-13 parts by weight of Seokchangpo, 9-13 parts by weight of Poria cocos, and 9-13 parts by weight of Astragali, and placing the second herbal medicine in a herbal medicine pouch to prepare a second herbal medicine pouch; A step for preparing a concentrated decoction solution and a first herbal medicine powder, comprising the steps of: placing the first herbal medicine bag and the second herbal medicine bag in a boiler containing purified water, and boiling at a temperature of 138-142°C for 160-200 minutes; after boiling, taking out the first herbal medicine bag and the second herbal medicine bag to prepare a decoction solution, and concentrating the decoction solution to prepare a concentrated decoction solution; and drying and pulverizing the first herbal medicine in the taken out first herbal medicine bag to prepare a first herbal medicine powder;
A step for preparing a mineral solution, comprising: a step of preparing a mineral powder by washing mite, quartz, topaz, feldspar, and yellow clay, grinding them, and mixing them in a weight ratio of 1:1:1:1:1; a step of preparing a mineral mixture by mixing 28-32 parts by weight of the mineral powder and 68-72 parts by weight of purified water; a step of heating the mineral mixture at a temperature of 118-122°C and extracting it for 5-7 hours; a step of maturing it at a temperature of 28-32°C for 2-4 days after the heating; and a step of filtering it after the maturation to obtain a filtrate;
A step for preparing a natural plant extract, comprising: a step of washing plum leaves, camellia leaves and pine leaves, and drying them at a temperature of 58-62°C for 2-4 hours; a step of grinding the dried plum leaves, camellia leaves and pine leaves, and mixing them at a weight ratio of 1:1:1 to prepare a leaf powder; a step of mixing 8-12 parts by weight of the leaf powder and 88-92 parts by weight of the mineral solution, and extracting them at a temperature of 88-92°C for 8-10 hours; and a step of filtering the extract through a filter paper, and subjecting the filtered filtrate to reduced pressure concentration and freeze-drying at -48-52°C; and
A method for producing a pharmaceutical composition for preventing or treating obesity, comprising: a step of producing a pill by mixing 58-62 parts by weight of the first herbal medicine powder, 18-22 parts by weight of the natural plant extract, 8-12 parts by weight of the concentrated decoction, and 8-12 parts by weight of bromelain powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020240016945A KR102755795B1 (en) | 2024-02-02 | 2024-02-02 | Method of manufacturing diet pills |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020240016945A KR102755795B1 (en) | 2024-02-02 | 2024-02-02 | Method of manufacturing diet pills |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102755795B1 true KR102755795B1 (en) | 2025-01-21 |
Family
ID=94389534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020240016945A Active KR102755795B1 (en) | 2024-02-02 | 2024-02-02 | Method of manufacturing diet pills |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102755795B1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130012110A (en) * | 2012-11-22 | 2013-02-01 | 김추부 | Corpulence control a well heap water boil a way |
| KR20130104692A (en) * | 2012-03-15 | 2013-09-25 | 김형준 | Composition foranti-obesity using extract of crataegi fructus |
| KR20190045073A (en) * | 2017-10-23 | 2019-05-02 | 주식회사 아리 생명공학 | Dietary herbal composition for improving obesity and method for producing the same |
-
2024
- 2024-02-02 KR KR1020240016945A patent/KR102755795B1/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130104692A (en) * | 2012-03-15 | 2013-09-25 | 김형준 | Composition foranti-obesity using extract of crataegi fructus |
| KR20130012110A (en) * | 2012-11-22 | 2013-02-01 | 김추부 | Corpulence control a well heap water boil a way |
| KR20190045073A (en) * | 2017-10-23 | 2019-05-02 | 주식회사 아리 생명공학 | Dietary herbal composition for improving obesity and method for producing the same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102450517B (en) | Broiler feed and traditional Chinese medicine additive used in same | |
| KR101408814B1 (en) | Korean medicinal tea and health functional food having strong antioxidant activity and high acceptabilitythe | |
| CN104856035A (en) | Health-care product for recuperating specific intrinsic constitution | |
| CN103340334A (en) | Freshwater fish feed and preparation method thereof | |
| KR20130029098A (en) | Mathod for manufacturing ion mineral using silk worm, muberry leaf, and muberry twig and health drink manufactured by this | |
| KR102577074B1 (en) | Manufacturing method of homemade snack of fishery products keeping its original form for companion animal and homemade snack of fishery products keeping its original form for companion animal manufactured using the method | |
| CN104856009A (en) | An eucommia ulmoides staminate flower health-care product | |
| KR101632794B1 (en) | METHOD OF MANUFACTURING PILL COMPRISED OF Protaetia brevitarsis seulensis | |
| CN106343343A (en) | Lithocarpus polystachyus (DC.) Rehd tartarian buckwheat composition for reducing three-high and application thereof | |
| CN108813501B (en) | Health-preserving honey paste with functions of clearing heat, moistening lung, relieving cough, reducing phlegm, relieving asthma and regulating human body functions | |
| CN104068177A (en) | Health-care life-lengthening natural plant tea | |
| KR101334827B1 (en) | Method making beauty art pack of the principal ingredient an stuff of a Melon seed oil | |
| CN116268152A (en) | Application of traditional Chinese medicine composition in preparing clear tea for improving throat discomfort | |
| KR100780552B1 (en) | Functional milk powder for infants and young children, including herbal medicines and manufacturing method thereof | |
| KR100986210B1 (en) | Health supplements | |
| KR102755795B1 (en) | Method of manufacturing diet pills | |
| KR102485016B1 (en) | Functional leached tea and manufacturing method of the same | |
| KR102755794B1 (en) | A method of manufacturing a pharmaceutical composition for the prevention or treatment of obesity | |
| KR102491631B1 (en) | Manufacturing Method of Wild Ginseng Syrup | |
| KR20120024186A (en) | A composition of health supplementary food and method thereof | |
| CN106937718A (en) | A kind of pair of marine alga pollen plant composite beverage and preparation method thereof | |
| KR100815333B1 (en) | Health food using herbal medicine and its manufacturing method | |
| KR20050080501A (en) | A making method of health assistance food for high blood pressure, fatness, diabetes patients. | |
| CN106212824A (en) | A kind of Fructus Fici herbal tea and processing technology thereof | |
| CN111758809A (en) | Astragalus membranaceus and samara leaf health-care tea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20240202 |
|
| PA0201 | Request for examination |
Patent event code: PA02011R01I Patent event date: 20240202 Comment text: Patent Application |
|
| PA0302 | Request for accelerated examination |
Patent event date: 20240202 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination Patent event date: 20240202 Patent event code: PA03021R01I Comment text: Patent Application |
|
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20240520 Patent event code: PE09021S01D |
|
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20241011 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20250113 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20250113 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |